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ABSTRACT
Protein glycosylation drives many biological processes and serves as marker for disease;
therefore, the development of tools to study glycosylation is an essential and growing area of
research. Mass spectrometry can be used to identify both the glycans of interest and the
glycosylation sites to which those glycans are attached, when proteins are proteolytically
digested and their glycopeptides are analyzed by a combination of high-resolution mass
spectrometry (MS) and tandem mass spectrometry (MS/MS) methods. One major challenge in
these experiments is collecting the requisite MS/MS data. The digested glycopeptides are often
present in complex mixtures and in low abundance, and the most commonly used approach to
collect MS/MS data on these species is data-dependent acquisition (DDA), where only the most
intense precursor ions trigger MS/MS. DDA results in limited glycopeptide coverage. Semi-
targeted data acquisition is an alternative experimental approach that can alleviate this difficulty.
However, due to the massive heterogeneity of glycopeptides, it is not obvious how to expediently
generate inclusion lists for these types of analyses. To solve this problem, we developed the
software tool GlycoPep MassList, which can be used to generate inclusion lists for liquid
chromatography tandem-mass spectrometry (LC-MS/MS) experiments. The utility of the
software was tested by conducting comparisons between semi-targeted and untargeted data-
dependent analysis experiments on a variety of proteins, including IgG, a protein whose
glycosylation must be characterized during its production as a biotherapeutic. When the
GlycoPep MassList software was used to generate inclusion lists for LC-MS/MS experiments,
more unique glycopeptides were selected for fragmentation. Generally, ∼30 % more unique
glycopeptides can be analyzed per protein, in the simplest cases, with low background. In cases
where background ions from proteins or other interferents are high, usage of an inclusion list is
even more advantageous. The software is free and publicly accessible.
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In another research project, we describe a unique flow cytometer (TDI SFC) that
combines the high spectral resolution of spectral flow cytometry (SFC) with a CCD operated in
time-delayed integration (TDI) mode for the automated immunophenotyping of rare, low
abundant cells. A microfluidic device providing 1-D focusing was used to sheath cells through a
488 nm laser excitation beam. Using epi-illumination, a spectrograph was included into the
emission optical path to spectrally disperse the emission along one axis of a CCD camera. The
parallel shift rate of the CCD was synchronized to the cell travel through the field-of-view,
which was defined by the excitation volume. This TDI SFC format allowed the CCD shutter to
remain open during signal acquisition and as such, the duty cycle was ~100% allowing for rare
cells to not be missed. Fluorescent calibration beads were used to optimize synchronization of
the CCD’s TDI clocking with the sheathed cell velocity, TDI SFC sensitivity, excitation power
intensity, epi-illumination objective’s numerical aperture, and total integration time. TDI
integrated signals of 106 counts at a signal-to-noise ratio (SNR) of 610 for beads corresponding
to a load of 4×105 antibodies per bead was achieved. Additionally, we evaluated the multiplexing
capabilities by performing spectral deconvolution. Finally, a proof-of-concept application was
undertaken to immunophenotype rare cells, specifically leukemic cells circulating in the blood of
patients with B-cell acute lymphoblastic leukemia (B-ALL) for monitoring measurable residual
disease (MRD). A B-ALL cell line was stained against a leukemic marker (TdT) to successfully
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CHAPTER I
Introduction to Analysis of Glycoproteins
1.1 Protein Glycosylation
Carbohydrates, lipids, proteins, and nucleic acids are the four major families of
macromolecules in cells. Among them, proteins exhibit the most diversity in structure and
function and participate in almost every biochemical process in cells.1 One reason for the
multiple and variant roles proteins are playing is post translational modifications (PTMs). PTMs
are covalent modification processes that occur in polypeptides, which often requires relevant
enzymes.2
One important and diverse PTM is glycosylation, which occurs in more than half of
eukaryotic proteins.3-5 Glycosylation refers to the process in which oligosaccharide moieties are
covalently attached to proteins. The oligosaccharides, also named as glycans, play significant
roles in protein structure stabilization and protein functions. For example, it is reported that the
hydrophilic hydroxyl group-rich glycans enhance the solubility and stability of proteins and
protect them from enzymatic degradation.6 Many proteins, especially cell surface proteins, are
glycosylated because glycoproteins as informational entities, play crucial role in cell-matrix
signaling 7,8, cell-cell interactions and immune response 9,10.
Beside the important roles of naturally produced glycoproteins in eukaryotes, the
significance of recombinantly expressed glycoprotein therapeutics is also tremendous. As
protein therapeutics, more and more recombinant monoclonal antibodies (rMAbs) from the
immunoglobulin G (IgG) family are licensed and produced due to their clinical significance and
the considerable revenue brought to the pharmaceutical industry.11 An ideal monoclonal antibody
therapeutic should have ideal structural stability, good efficacy for a specific disease, and limited
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side effects. Almost all of these features heavily depend on the monoclonal antibody drug’s
glycosylation profile.11,12 For example, antibodies with high mannose glycans are cleared faster
in human serum.13 Glycans containing NeuGc can cause an unwanted immune response.12
Therefore, characterization of glycoproteins has attracted much attention due to their great
potential in unraveling the mechanisms of many biological processes and developing new
pharmaceuticals.7,8,14-16
The building blocks of glycans include but are not limited to mannose, galactose, fucose,
N- acetylglucosamine and N-acetylneuraminic acid. In order to present the sugar residues in an
efficient way, a set of colorful symbols proposed by the Consortium for Functional Glycomics to
represent monosaccharide residues are applied to simplify the structural representations of
glycans.17 Some of these symbols and the monosaccharide residues they represent as well as their
abbreviations are shown in Figure 1.1.
Figure 1.1Monosaccharide residues’ chemical structures, symbols, names and abbreviations.
Mannose (Man) Galactose (Gal) Fucose (Fuc)
N-acetylglucosamine (HexNAc) N-acetylneuraminic acid (NeuAc)
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1.1.1 N-linked Glycosylation
In this thesis, only N-linked glycosylation is studied. N-linked glycosylation is one of the
most investigated glycosylation types among the existing forms of glycosylation in nature.18 In
N-linked glycosylation, the glycan forms a covalent bond with the side-chain amine group of an
asparagine residue (Asn or N) following a consensus amino acid sequence of NXS/T (where X
can be any amino acid residue except proline).19 It should be noted that although all N-linked
glycoproteins require such a preserved amino acid sequence, the presence of such peptide
backbone sequence does not necessarily guarantee glycosylation at that site.20 This phenomenon
also extends to other types of glycosylation.
The process of glycosylation depends on the protein’s microenvironment and enzyme
availability as opposed to peptide backbone biosynthesis controlled by the genome. Each mature
N-linked glycoprotein stems from a precursor glycoprotein linked with a precursor glycan of
Glc3Man9GlcNAc2. The precursor glycoprotein is biosynthesized in the endoplasmic reticulum
(ER) lumen under the catalysis of multiple oligosaccharide transferases (OSTase).21 Mature
glycans are formed by truncating and extension of the precursor glycan in ER and/or Golgi
apparatus.21 Despite the fact that trimming and extension happen to the precursor glycoprotein,
the core moiety of five oligosaccharide residues linked to the asparagine residue is usually
retained. This gives rise to the preserved core motif of two N-acetyl glucosamine residues and
three mannose residues in N-linked glycans22, as shown in Figure 1.2.
Depending on the compositions of the N-glycans, they can be divided into three
subgroups: high mannose, complex, and hybrid as shown in Figure 1.2. A high mannose glycan
is formed by removing the mannoses from the precursor glycan without adding new
monosaccharides. A complex glycan is formed by removing and adding sugars to the precursor
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glycan. A hybrid glycan, as self-explained by its name, is a combination of the building blocks of
both high mannose and complex glycans.22
Figure 1.2 N-linked glycans have a conserved moiety of Hex3HexNAc2. All N-linked glycans
can be divided into three subgroups, high mannose, complex and hybrid.
1.1.2 Other Types of Glycosylation
Besides N-linked glycosylation, there are other forms of glycosylation. Another widely
studied type is O-linked glycosylation. In O-linked glycosylation, glycans are attached to the
hydroxyl group of a serine or threonine residue (preserved amino acid sequence S/T).23 Less
common glycosylations include glypiation24, C-glycosylation25, and phosphoglycosylation26.
1.1.3 Heterogeneity of Glycosylation
Unlike the biosynthesis of a protein peptide backbone, which is templated by the genome,
the process of glycosylation is not a templated process. Instead, it is largely determined by the
availability of related enzymes, such as glycosyltransferase and glycosidase. This results in
heterogeneity of the glycoprotein population.22,27 An example of the macroheterogeneity and the
microheterogeneity of a glycoprotein is illustrated in Figure 1.3.
Conserved moiety High mannose Complex Hybrid
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Figure 1.3Macroheterogeneity and microheterogeneity of glycosylation
This variance of glycosylation site occupancy is called macroheterogeneity.28 With
macroheterogeneity, for one specific glycosylation site, the degree of glycosylation may not be
100%. The site may or may not be glycosylated, depending on the different copies of the proteins.
Microheterogeneity, on the other hand, corresponds to the attachment of different glycans to the
same glycosylation sites in different copies of proteins.28 Heterogeneity renders glycoproteins in
low abundance and thus makes glycoprotein/glycopeptide analysis challenging.
1.1.4 Enrichment of Glycoproteins/glycopeptides
In order to alleviate the difficulty brought about by the low abundance of glycoproteins,
enrichment strategies for glycoproteins or glycopeptides are frequently utilized. The positive
selection and enrichment greatly reduces the sample complexity, decreasing the interference
brought about by non-glycosylated substrates.29
Enrichment can be categorized into molecular interaction and chemical reaction based
methods.29 Molecular interactions include hydrophilic interaction, lectin affinity interaction, and
titanium dioxide-based coordination interaction while chemical reactions encompass hydrazide
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and boronic acid chemistry.29 Among the former group of enrichment methodologies/methods,
hydrophilic chromatography and lectin affinity chromatography are frequently employed for N-
linked glycopeptide enrichment.30 In hydrophilic interaction liquid chromatography (HILIC),
multiple hydroxyl groups-containing glycopeptides partition between the hydrophobic mobile
phase and hydrophilic stationary phase, allowing for enrichment.31 However, the non-specific
hydrophilic interaction can result in co-enrichment of many polar groups containing compounds
from the sample matrix, which dampens the goal of glycopeptide enrichment.30 Lectins are
proteins that have selective recognition and binding for certain groups of oligosaccharide
moieties.32 The commonly used lectins are concanavalin A (Con A) mainly with specificity for
mannose, jacalin for galactosyl (β1-3) N-acetylgalactosamine and wheat germ agglutinin (WGA)
for N-acetyl glucosamine and sialic acid.32 Although lectin affinity chromatography (LAC) has
the feature of high specificity, the preferential affinity to a subset of glycans can cause sample
loss.33 Chemical reaction based glycopeptide enrichment has less discrimination against the
subgroups of glycans.34 However, the recovery is largely dependent on the releasing step.32 In
addition, hydrazide chemistry detached the glycan parts from the peptides, hindering the
localization of glycosites.34
In summary, although glycopeptide analysis benefits from glycopeptide enrichment, the
weak binding, biased affinity and multiple sample preparation steps hamper the purpose of
nondiscriminatory identification and impede the goal for high glycopeptide coverage.
1.2 Analysis of Glycoproteins
Since glycoproteins are involved with proteins and glycans, the analysis of glycoproteins
is more challenging than the analysis of mere proteins or glycans. In addition, heterogeneity of
glycoproteins adds one more dimension of complexity and difficulty to the analysis. Generally,
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the analysis of glycoproteins can be achieved by non-mass spectrometry based approaches and
mass spectrometry based approaches.
1.2.1 Non-mass spectrometry Approaches
The most common non-MS based approaches include but are not restricted to sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) staining and affinity selection
coupled with fluorescence detection.23 These approaches tell whether a protein has been
glycosylated.
Gel staining with SDS-PAGE uses periodic acid to oxidize two vicinal diol groups to
form an aldehyde group, which reacts with a Schiff reagent to produce a magenta color.35 In
another strategy, enzyme Peptide-N-glycosidase F (PNGase F) is used to deglycosylate the
protein, which shows mass differences with the PNGase F-untreated protein on SDS-PAGE, to
reveal if a protein is glycosylated.36
In affinity based procedures, glycoproteins are captured by immobilized antibodies,
which is followed by the addition of an enzyme conjugated secondary antibody. The affinity
selection coupled with fluorescence generation catalyzed by the enzyme enables the
determination of glycosylation.23
Other non-MS methods include HPLC separation coupled with fluorescence
detection.37,38 Most naturally produced glycans possess minimal to no fluorescence. But they can
be derivatized with fluorescent labels, such as 2-amino benzamide (2 AB) or 2-anthranilic acid
(2 AA), and make fluorescence detection feasible.38
The non-MS based methods are relatively simple and straightforward. However, they
lack the ability of giving information on the peptide backbone sequence or the glycan
compositions. To obtain this valuable information, mass spectrometry is often utilized.
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1.2.2 Mass Spectrometry Based strategies
Over the past decades, mass spectrometry (MS) has demonstrated its invaluable merits in
characterizing PTMs39-41, including glycosylation42,43. A frequently adopted workflow for
glycoprotein analysis using MS involves bottom-up proteomics. In bottom-up proteomics,
peptides generated after enzymatic digestion are subjected to High Performance Liquid
Chromatography (HPLC) tandem mass spectrometry (MS/MS) for in-depth analysis.44,45
Regardless of the type of mass spectrometer being used, a mass spectrometer usually
consists of the following three major units: (1) an ion source to ionize the analytes, (2) a mass
analyzer to separate the analytes based on different mass-to-charge ratios (m/z), and (3) a mass
detector to detect the analytes. In order to be analyzed by a mass spectrometer, the analytes must
be ionized. Therefore, the ion source is very important because it determines what type of
analytes or application is suitable for the specific mass spectrometer. There are different ion
sources such as electron impact (EI), chemical ionization (CI), fast atom bombardment (FAB)46,
electrospray ionization (ESI)47 and matrix-assisted laser desorption ionization (MALDI)48. The
later three are known as “soft ionization” methods due to their mild pathways to ionize biological
molecules, such as proteins and deoxyribonucleic acids (DNA), without remarkable
decomposition of molecular structure.49,50
MS first successfully identified a glycopeptide primary structure in 1970s by using EI
and CI.51 The glycans from the glycopeptides were released and derivatized to increase the
volatility so that they could be detected by MS.51 In the late 1980s and early 1990s, the sprout
and development of “soft ionization” techniques, electrospray ionization (ESI)47,52 and matrix-
assisted laser desorption ionization (MALDI)48,53, promoted mass spectrometry into a
revolutionary area where analysis of biological macromolecules by MS became much more
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feasible54,55. John Fenn and Koichi Tanaka, pioneers of ESI and MALDI, respectively, were
awarded the 2002 Noble Prize in Chemistry for their significant contribution to the field. In ESI
and MALDI, the non-volatile glycoproteins or glycopeptides can be ionized without significant
structure disruption or loss of labile groups.56,57 Because of the commercial availability of ESI
and MALDI, these two soft ion sources have been frequently applied to analyze glycoconjugates
and glycoproteins.9,25,58
Particularly, the marriage of ESI and HPLC further boosted mass spectrometry’s
capability for the analysis of glycoproteins.59-62 The online separation provided by HPLC
coupled with mass detection increases the data and information obtained in one single
experiment and enables the analysis of complex biological samples.63,64
1.2.2.1 Glycopeptide Analysis by MS1
After the glycopeptides are ionized, they can be separated by mass analyzers such as a
quadrupole ion trap65, orbitrap66, Fourier Transform ion cyclotron resonance (FTICR)67, or Time-
of Flight (TOF) spectrometer. In mass analyzers engineered with electric and magnetic fields,
ions with different m/z values deflect at different degrees allowing separation of them.50 Due to
the different features of these mass analyzers and the detectors coupled to them, they can be
quite different in terms of cost, speed, resolution and dynamic range. For example, the
quadrupole ion trap is best known for its fast scan rate whereas orbitrap is frequently used for its
high resolution data.
High resolution ESI MS1 data is very useful in glycopeptide analysis as the mass error
within several ppm can help to define the possible glycopeptide compositions.68 Nevertheless,
high mass accuracy data, in some cases, are not sufficient to rigorously identify the glycopeptide
because there are numerous combinations of amino acids with oligosaccharides. The isobaric
10
MS1 data may result in misclassification of glycopeptides and lead to wrong conclusions.68 In
this case, MS2 or MS/MS data are needed to verify the analysis and eliminate the possibility of
misidentification.
1.2.2.2 Glycopeptide Analysis by MS/MS
Collision induced dissociation (CID) is a widely used dissociation method, where
glycosidic fragment ions as well as peptide backbone b and y ions are produced due to
vibrational activation69, enabling the identification of glycopeptides. In this low-energy pathway
dominated process, the predominant dissociation of glycan parts gives rise to oxonium ions
(NeuAc+, m/z 292; HexHexNAc+, m/z 366; HexHexNAcNeuAc+, m/z 657)70 that are diagnostic
ions of glycopeptides19. Another advantage of CID is the fast scan speed enabled by the ion
trap65, allowing for simultaneous elucidation of multiple glycopeptides sharing the same peptide
sequence but different glycans when coeluting in a reverse phase LC column71. However, despite
the ability to precisely identify glycopeptides, glycopeptide analysis by CID still suffers from the
intrinsic low abundance nature of glycopeptides. The macroheterogeneity that comes from the
difference of glycosylation site occupancy and the microheterogeneity that results from the
attachment of different glycans to one specific glycosylation site render each glycoform in a low
copy number after proteolysis.5,28 Consequently, in the most commonly used MS/MS data
dependent acquisition (DDA) mode where the most intense peptide ions on MS are selected for
MS/MS, the high-abundance precursor ions are redundantly selected for MS/MS while the
relatively low abundant glycopeptide ions may not trigger MS/MS even if dynamic exclusion is
enabled.72 This results in missed detection of glycopeptides and limited glycopeptide coverage.
This hurdle is especially serious when the sample has a complex matrix that brings high
background corresponding to non-glycosylated peptides. The goal of the research work discussed
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in Chapter 3 is to alleviate this problem by developing a new software tool and a different
MS/MS strategy from the most commonly used one.
Electron transfer dissociation (ETD) is another commonly used fragmentation method for
glycopeptide analysis. Unlike CID, ETD predominantly generates fragment ions from peptide
back bone cleavage.73 This is due to its radical induced fragmentation pathways instead of
vibrational energy controlled pathways in CID. Figure 1.4 exhibits the difference of
fragmentation behavior of CID and ETD.
Figure 1.4 (A) In CID fragmentation mainly occurs at glycosidic bonds. (B) In ETD dissociation
primarily occurs at peptide backbone bonds. (C) CID MS/MS data of an N-linked high-mannose
avidin glycopeptide (z=2, m/z=1527.66).
Besides CID, new MS/MS strategies have also been developed for glycopeptide
identification. Hart-Smith and colleagues investigated using high resolution MS1 and higher
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energy C-trap dissociation (HCD) to identify N-linked glycopeptides from a hen egg
glycoprotein mixture.74 The HCD MS/MS detected by orbitrap was featured with high resolution
data and the absence of 1/3 low-mass cutoff found in the ion trap. The high mass accuracy of the
Y1 ions (peptide + HexNAc ions) and oxonium ions from HCD data ensured the confirmation of
glycopeptides.74
Singh and coworkers performed ETD triggered by HCD oxonium product ions to analyze
glycopeptides.75 In their approach, when the oxonium peaks (HexNAc+, m/z 204.09;
HexHexNAc+, 366.14) were among the top 20 intense fragment peaks on HCD MS/MS, a
subsequent ion trap ETD scan would be performed on the same precursor ion.75 HCD mainly
generated the glycosidic fragment peaks.76 ETD primarily produced peptide backbone c and z
ions with the heterogeneous glycans largely retained, enabling peptide backbone sequencing and
glycosite localization.77 The complementary information obtained from HCD and ETD served a
robust tool for glycopeptide analysis.75 However, the high resolution orbitrap HCD MS/MS
scans had longer duty cycle in comparison with ion trap CID MS/MS, resulting in less HCD
MS/MS scans during the same time. In addition, in the abovementioned strategies involving
HCD the commonly used DDA was used, which meant only the top intense precursor ions on
MS1 preview scan were selected for MS/MS. Nevertheless, because of the low abundance of
glycopeptides most of the selected precursor ions for MS/MS in DDA mode did not correspond
to glycopeptides. The long cycle time and biased ion selection can be detrimental if broad scale
glycopeptide identification is desired.
1.3 Challenges in MS/MS Analysis of Glycopeptides
During the commonly used MS/MS data collection process where the DDA mode is used,
the relatively low abundance glycopeptide ions may not trigger MS/MS in this intensity based
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ion selection process. This results in the absence of MS/MS data of some glycopeptides, leading
to limited glycopeptide coverage, as indicated by Figure 1.5.
Figure 1.5 In the commonly used DDA mode the most abundant parent ions, for instance, the
top 10 ions indicated by red numbers, on a MS1 scan are selected for MS/MS. The glycopeptide
ions with low abundance, such as the one indicated with blue arrow, are not selected for MS/MS
scan.
1.4 Conclusion
Analyzing glycopeptides by MS1 is essential. Due to the numerous combination of
glycans and peptide backbones, analyzing glycopeptide merely by MS1 data is not adequate to
confirm the analytes due to the numerous possible isobaric glycopeptides. Hence, MS/MS data
are usually needed to accurately verify the analysis. In the commonly used DDA mode during
MS/MS data acquisition, the ion selection for MS/MS is based on intensity of the parent peak on
MS1 scan. When there are low-abundance glycopeptide species, they may not trigger MS/MS
due to their low peak intensity on MS1, decreasing the glycopeptide coverage. Semi targeted
data acquisition is an alternative that can alleviate this issue. In this approach, a list of pre-
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assigned glycopeptide masses is used to trigger MS/MS. However, accurately generating a large
number of glycopeptide masses can be time-consuming. Hence, new software tools is needed for
facilitating this strategy to circumvent the challenges in DDA.
1.5 Protein Analysis vs Cell Analysis
Analysis of glycoprotein by MS has attracted lots of researcher interest because
glycoproteins are not only involved in many biological processes, such as fertilization78, inter-
cell signaling32, and antibody-antigen bindings79, but also serve as potential disease markers 80,81.
For example, increased core fucosylation of alpha-fetoglycoprotein (AFP) was reported to
associate with hepatocellular carcinoma (HCC), a type of liver cancer, and thus could be used as
a biomarker for HCC in patients infected with Hepatitis B virus (HBV) or/and Hepatitis C virus
(HCV).81
Although glycoproteins may serve as potential disease detection markers, what is needed
is a biomarker to track disease progression. Many times the disease detection marker may not
necessarily enable the knowledge of disease progression. For instance, increased core
fucosylation on alpha-fetoglycoprotein (AFP) indicates highly possible HCC in HBV or/and
HCV infected patients. However, the information provided by MS is insufficient to provide
knowledge about the progression or severity of the disease. Directly analyzing the anatomically
accessible specimens is capable of unraveling more information related to the number and/or
percentage of the malignant cells and enables the knowledge of the disease progression or
severity. Due to its unique physical features, MS is unable to analyze anatomically accessible
specimens. In this situation, other bioanalytical methods that are able to analyze tissue or cell
samples from cancer patients are highly needed. Flow cytometry is one of such bioanalytical
methods that can analyze cells from patients, of which the majority are leukemia patients.
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CHAPTER II
Introduction to Detecting Circulating Leukemia Cells for
Monitoring Relapse from Minimal Residual Disease
2.1 Leukemia and Minimal Residual Disease
2.1.1 Leukemia Introduction
Inside our bones is bone marrow (BM) that contains hematopoietic stem cells (HSCs).
During hematopoiesis, HSCs differentiate into common myeloid progenitor cells and lymphoid
progenitor cells both of which further differentiate into red blood cells (RBCs), white blood cells
(WBCs) and platelets that comprise the formed components of blood.1,2 However, in leukemia
the HSCs or progenitor cells in the BM acquire mutations and result in abnormally high numbers
of white blood cells (WBCs) that carry out minimal to no useful functions.2 These cancerous
cells usually overproduce, leading to decreased number of normal RBCs, WBCs, and platelets,
causing symptoms such anemia, fatigue, and easy bruising in patients.3 Because the malignant
cells do not properly perform functions like healthy WBCs do, leukemia patients also suffer from
compromised immune systems.3
Depending on the onset and lineage of the disease, leukemia is mainly divided into four
subgroups: acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute
lymphocytic leukemia (ALL) and chronic lymphocytic leukemia (CLL).4 Leukemia is usually
noticed or diagnosed with an extremely high number of WBCs from a blood test.5 To confirm
the diagnosis and determine the subtype of the disease, more tests such as morphological tests6,7
and flow cytometric tests8,9 are usually undertaken.
Treatments for leukemia include chemotherapy and stem cell transplantation, depending
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on the disease state as well as the age and health conditions of the patient.9,10 Once the diagnosis
is confirmed, induction therapy is usually applied, especially in acute leukemia patients11, to
remove as many leukemic cells as possible . Detection of leukemic cells after treatment is
essential because it is critical for monitoring disease progression and guiding treatments.12,13
2.1.2 Detection of Leukemic Cells
2.1.2.1 Morphology
(A) (B)
Normal bone marrow B ALL bone marrow
Figure 2.1 Normal bone marrow (A) contains hematopoietic cells in various stages of maturation.
Bone marrow of a patient with acute leukemia (B) is filled with monotonously appearing large
leukemic blasts. Reproduced from Ref. 3 with permission from The American Academy of
Pediatrics.
Standard clinical tests for leukemic cells include morphology and flow cytometry.6,14
Morphological examinations have been a requisite for leukemic cell evaluation and diagnosis15,
and post-remission disease monitoring.16 Morphological examinations mainly provide
information on the leukemic cells’ size and appearance, which is evaluated using an optical
microscope.15 For example, myeloperoxidase (MPO) is a cytoplasmic protein highly expressed in
the neutrophils of the myeloid lineage. Immunohistochemical staining for MPO can be used to
detect leukemic blasts in AML patients17. Wright Giemsa Stains are also frequently used for
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bone marrow smear.3,6 The major components are methylene blue and its oxidative forms, azure
A and azure B, and eosin.18 They stain erythrocytes (RBCs) with pink, leukocyte nuclei with
blue to purple and platelet cytoplasm with dark lilac.18 The morphological images with Wright
Giemsa staining of a normal and a B ALL bone marrow smear are shown in Figure 2.1.
However, having a sensitivity of 1-5% leukemic cells/WBCs 19,20 makes this test far from
sensitive or discriminative to search for early stages of disease when the normal blood cell
population is higher than 95% of the cell population. In addition, morphology possesses limited
ability to discern key marker expression on leukemic cells to precisely distinguish leukemic cells
from normal leukocytes or to discriminate leukemia-associated immunophenotypic abnormalities
that can be used to guide therapeutic decisions.21
2.1.2.2 Flow Cytometry
Flow cytometry tests are often used to gain more insight into the disease state.22 In flow
cytometry, cells are incubated with fluorophore-conjugated antibodies that are specific to cell
markers and are then hydrodynamically injected into a flow cell in a single line fashion and
illuminated by a laser beam to secure information on protein markers, cell size and cell
granularity.23 The fluorescent dye emission are related to the cell markers and provide
information on the absence or presence of certain markers and their expression level.24 The most
used markers for leukemic cells are cluster of differentiation (CD) markers. CD markers are a
family of highly diverse membrane proteins mainly expressed on white blood cell surfaces or
other immune system-related cells.25
Not only more descriptive than morphology, flow cytometry is also more sensitive with a
sensitivity of 10-3 to 10-4 leukemic cells/WBCs.20 However, this sensitivity is still insufficient for
detecting low levels of leukemic cells in patients. Additionally, flow cytometric tests generally
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require BM biopsies, which are highly invasive and painful. Figure 2.2 displays the general
workflow in conventional flow cytometry.
Figure 2.2 General workflow typically used in traditional flow cytometry, which includes taking
bone marrow biopsy, staining the marrow cells, and introducing the cell sample into a flow
cytometer for sample and data analysis.
2.1.2.3 Minimal Residual Disease
With current induction treatments, most leukemia patients have complete remission (CR),
which is defined by the presence of less than 5% of leukemic blasts in the bone marrow through
morphological assessment.13,26,27 However, CR does not necessarily ensure positive patient
outcome. The persistent leukemia cells after therapy, termed as minimal residual disease (MRD)
28, although low in numbers, may harbor drug resistance, reproduce to disease burden and cause
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relapse15,27. Because the progression of leukemic MRD is associated with disease progression
and serves as an important prognosticator to allow for tailoring treatments and predicting patient
outcome, obtaining information on the numbers and phenotypic features of leukemic MRD is of
paramount importance.12,22,29 For example, when the MRD level cannot be properly monitored
and similar maintenance therapies are given to all acute leukemia patients with CR, the non-
targeted treatments may not be effective.15 Specifically, the treatments may be overdose or
unnecessary to patients with extremely low level MRD who are basically cured. On the other
hand, the same treatments may be impotent or inappropriate to patients who have elevated level
of MRD, making the treatment not efficacious preventing relapse. Only when the MRD level is
precisely monitored in a timely manner can the appropriate patient-specific clinical actions be
implemented.
However, the commonly used tests to monitor MRD lack the ability to pinpoint relapse
from MRD due to their limited sensitivity. Hence, highly sensitive analytical methods are in
high demand to meet this clinical need.
2.1.2.4 Detection of Leukemic Cells by Microfluidics
To address this challenge, our group previously developed a highly sensitive microfluidic
assay to detect circulating leukemic cells (CLCs) from peripheral blood (PB) samples instead of
BM for AML patients.30 Briefly, 3 mL of PB from each AML patient was infused into three
different sinusoidal microfluidic chips to affinity isolate three subgroups of leukemic cells. The
enriched cells were then rinsed with buffer, stained with fluorochrome-linked antibodies specific
to cell markers, released through cleavable linkers , and immunophenotyped by semi-automated
fluorescence microscopy.30 This assay greatly increased the sensitivity of leukemic cell detection
in PB. Despite the heterogeneous leukemia-associated phenotypes in AML patients31, the
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microfluidic assay could detect 11-2684 leukemic cells/mL of blood for MRD patients. In
addition, the assay obviated the requirement for an invasive BM biopsy, giving rise to higher
sampling frequency. For instance, we could sample every week instead of every 2-3 months with
bone marrow biopsy, allowing for closer monitoring of the disease. An illustration of this
microfluidic assay is shown in Figure 2.3.
Figure 2.3 Detecting circulating leukemic cells (CLCs) from PB samples instead of BMs in
AML patients. 3 mL of blood from each AML patient was perfused into three sinusoidal
microfluidic chips to affinity isolate three subgroups of leukemic cells. The enriched cells were
then rinsed with buffer, stained with fluorochrome-linked antibodies specific to cell markers,
released through cleavable linkers, and immunophenotyped by semi-automated fluorescence
microscopy. Reproduced from Ref. 30 with permission from The Royal Society of Chemistry
2.1.2.5 Immunophenotyping Microfluidic Chip-isolated Leukemic Cells by Fluorescence
Microscopy
Fluorescence microscopy is a frequently used tool to immunophenotype cells to discern
the presence of different markers.30,32 The primary reason for the use of fluorescence microscopy
is because it represents standard equipment in many labs33, and possesses a relatively long
history of use in clinical settings34. However, the data collection and processing normally require
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multiple processing steps with various algorithms to generate accurate results, which eventually
makes it challenging in terms of throughput.33 This is particularly true when there are many cells
in each sample or there are a lot of samples to be analyzed. For example, our AML microfluidic
assay imaged the wells of microliter plates where the enriched leukemic cells were deposited
following enzymatic release from the microfluidic chip. Due to the high number of cells and the
semi-automated nature of the assay, the immunophenotyping of cells from a single chip
required >8 h of processing time.
2.2 Flow Cytometry with Time Delayed Integration
2.2.1 Standard Flow Cytometry and Its Incompatibility with Microfluidic chip-isolated
Cells
An alternative immunophenotyping method that possesses higher throughput compared
to fluorescence microscopy is flow cytometry. Flow cytometry is a widely used tool for cell
counting and immunophenotyping with higher automation capabilities compared to fluorescence
microscopy.35 Nevertheless, flow cytometry requires large numbers of cells to generate
statistically reliable results. While it can process thousands of cells36, in some cases up to 20,000
cells s-1 in modern flow cytometers37, it does require at least thousands of cells to set up the
proper gating levels and perform spectral compensation for channel cross-talk. However, in our
microfluidic assay, the number of cells isolated from each microfluidic chip is normally in the
range of several hundred to several thousand30, far less than the amount of cells needed for
standard flow cytometry to set up proper gates. Thus, the microfluidic chip-isolated cells can
scarcely be analyzed by traditional flow cytometry. The spectral cross-talk in traditional flow
cytometry is depicted in Figure 2.4.
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Figure 2.4 Spectral cross-talk in a standard flow cytometer with a 488 nm excitation light source.
From left to right, the solid lines with color fillings are the fluorescence emission spectra of the
four dyes FITC, PE, PE-Cy5 and PE-Cy7. The rectangles indicate the wavelength rages of the
data collected by flow cytometry with bandpass filters. However, the data collected in each
channel not only include the fluorescent photons from the dye of interest in that channel, but also
the photons spilled over from other dyes due to spectral overlap. To tackle this issue, singly-
stained control samples and experiments are necessary to perform spectral compensation. Figure
simulated and reprinted from Fluorescence SpectraViewer on Thermo Fisher Scientific official
website with permission38.
2.2.2 Spectral Flow Cytometry with Time Delayed Integration
To address the gap between the time-consuming fluorescence microscopy and cell
number-demanding flow cytometry, we present here a novel spectral flow cytometer with time-
delayed integration (TDI). Instead of using filters for fluorescence color sorting, we employed a
spectrograph so that the entire spectrum of the labeling dye could be interrogated so that spectral
deconvolution could be employed to better identify the fluorescent labels attached to cell-
resident molecules. This TDI spectral flow cytometer (TDI SFC) was designed to enumerate and
immunophenotype chip-isolated leukemic cells from patients’ PB samples. It should be noted
that theoretically, not only leukemic cells but also any fluorescently stained cells can be analyzed
using this TDI SFC.
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2.2.2.1 Spectral Flow Cytometry vs Traditional Flow Cytometry
Figure 2.5 Fluorescence color-sorting differences between a traditional flow cytometer and a
spectral flow cytometer. While the traditional flow cytometer uses dichroic mirrors and bandpass
filters to collect light signals at certain wavelength ranges that are processed on separate
photodetectors, the spectral flow cytometer utilizes dispersive optics, for example a spectrograph,
to disperse light and collect the entire spectrum with the multi-color light processed on a CCD
camera. Reproduced from Ref. 39 with permission. Copyright 2013 John Wiley and Sons.
The primary difference between a traditional flow cytometer and a spectral flow
cytometer resides within the optics and the photon signal they collect. While the traditional flow
cytometer uses dichroic mirrors and bandpass filters to collect light signals at certain wavelength
ranges, the spectral flow cytometer utilizes dispersive optics, for example, a spectrograph, to
disperse light and collect the entire fluorescence emission spectrum.39 Subsequently, spectral
deconvolution is usually implemented to resolve each individual spectrum from the total
spectrum. Although the two cytometers may share the same fluidic system, spectral flow
cytometry allows for higher usage of the fluorescence emission because the entire emission
spectrum is recorded. This results in advantages over traditional flow cytometry. For instance, in
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traditional flow cytometry, care must be taken when using dyes that exhibit significant spectral
overlap. But, using these dyes is not problematic in spectral flow cytometry because spectral
deconvolution is performed to resolve the individual spectrum from each dye.40 The differences
in the color sorting optical trains between a traditional flow cytometer and a spectral flow
cytometer is shown in Figure 2.5.
2.2.2.2 TDI mode: How It Works and What It Can Do
Our TDI SFC utilizes a Charge-Coupled-Device (CCD) photon detector, distinguishing it
from a traditional flow cytometer, which uses photomultiplier tubes (PMTs) or/and photodiodes
(PDs). In our case, the CCD is programmed to operate in a time-delayed integration (TDI) mode.
TDI has been widely used in remote imaging systems to acquire high resolution images of
moving objects with weak light.41 However, the TDI mode of CCD operation has only rarely
been applied in bioanalytical chemistry.42,43 Briefly, the advantage of using the TDI mode as
compared to a snapshot CCD operational mode is: (1) The duty cycle of TDI is much better than
the snapshot mode because in TDI, the shutter remains open during the entire experimental run;
and (2) the signal-to-noise ratio (SNR) for TDI is higher than the snapshot mode with the gain in
SNR approximately equal to n1/2, where n is the number of CCD pixels in a single column.
On a CCD image sensor, multiple pixels collect light signals from an object and
transduce them into charge signals. By applying proper electrical conditions, the charge signals
are simultaneously shifted across the pixel rows (also known as parallel registers) and go to the
serial register to be read out.44 TDI mode eliminates the need for a shutter and takes advantage of
the signal shifting process.45 Namely, the object’s linear velocity and the CCD’s parallel shift
rate or readout rate are synchronized so that the photoelectrical signal will accumulate in only a
few pixel rows at readout, increasing the SNR.41 With TDI SFC, each pixel row records a
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spectrum, while the pixel column contains the single cell signal. A schematic of a fluorescently
labeled cell being processed using the TDI SFC is shown in Figure 2.6.
Figure 2.6 Schematic detecting a fluorophore-labeled cell in our TDI SFC. Because the cell’s
linear velocity and the CCD’s readout rate are synchronized, as the cell moving forward on the
shift axis, the fluorescent signal is transported and integrated within only a few pixel rows at
readout. Each pixel row on spectral direction collects a full spectrum due to the spectrum
dispersion by the spectrograph.
2.2.2.3 Critical Factors when Operating TDI SFC
2.2.2.3.1 Synchronization of Particle Moving with CCD Readout
Due to the unique features of the TDI SFC, there are several factors where attention
should be paid to facilitate successful experiments. First and foremost, it is critical to
synchronize the linear velocity of the fluorescent particle with the pixel row shift rate of the CCD.
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Only in this case can the signal be accumulated within a few pixel rows and optimal SNR be
obtained.42 If the particle’s linear velocity is not synchronized well with the CCD’s pixel row
shift rate, there will be image blurring and the photoelectrical signal will be distributed over
multiple pixel rows, reducing the SNR.
2.2.2.3.2 Focusing of Particles
It is widely accepted that in microfluidic channels with pressure-driven flow, due to the
flow’s parabolic nature dictated by Reynold numbers (Re) <2000, the linear velocities of the
fluorescent particles near to the channel wall are lower than that at the centerline.46,47 The
parabolic profile of the flow in microfluidic channels is illustrated in Figure 2.7.
Figure 2.7 The parabolic flow profile in microfluidic channels. In typical microfluidic channels
where Re is far below 2000, the fluid’s linear velocity at the wall is lower than that at the channel
centerline. It results in position-dependent non-uniformity of linear velocities in the channel.
Adapted from Ref. 47 with permission from The Royal Society of Chemistry.




where ρ is the density of the fluid (kg/m3), u is the velocity of the fluid with respect to the object
(m/s), L is a characteristic linear dimension (m) of the channel and μ is the dynamic viscosity of
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the fluid (Pa·s or N·s/m2 or kg/m·s). This is exacerbated by the no-slip condition, where the
velocity at the wall is zero and thus, giving rise to Taylor dispersion.
Usually, the CCD’s parallel shift rate is constant during an experiment. However, due to
the flow’s parabolic nature in the microfluidic channel, the fluorescently labeled analytes in the
flow possess various linear velocities, making it difficult to synchronize the analytes’ velocities
with the CCD’s parallel shift rate. Hence, this nonuniformity of the particles’ linear velocities is
unwanted if optimal synchronization is desired.
A strategy to obviate this issue is to use hydrodynamic flow focusing, in which a sheath
flow is used to surround the sample flow. Because the sheath is operated at a higher velocity than
the sample stream velocity, the sample velocity is accelerated and thus, focuses to the centerline
of the flow where the velocity becomes more constant, and thus can match the parallel shift rate
of the CCD with the linear velocity of the biological cells to be interrogated. The added benefit is
that the cells also align themselves into a single file so that each cell can be processed
individually; the sampling efficiency for single cells increases dramatically compared to non-
focused flow.
2.3 Flow Device for TDI SFC
2.3.1 T Shaped Microfluidic Chip
To facilitate the synchronization of the analytes with the CCD’s parallel shift rate in TDI,
a microfluidic flow cell adopting a simple T shape has been fabricated to hydrodynamically
focus the analytes within the microfluidic channel. This flow cell is capable of confining the
fluorescent particles into a relatively narrow cross-area at the channel center and enhancing the
uniformity of their linear velocities. In terms of fabricating the microfluidic flow cell, poly
(methylmethacrylate), PMMA, a cheap and easily accessible plastic, was used as the substrate.
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The fact that PMMA possess excellent optical transparency48,49, relatively low autofluorescence48
and its refractive index (RI) is very close to glass (PMMA RI=1.5049,50 and glass RI=1.5151 at
488 nm, respectively) made it an ideal substrate for the TDI SFC application. Additionally,
PMMA has minimal water absorption, greatly reducing the possibility of channel deformation
after multiple times of usage. Channel deformation is detrimental to TDI because it can cause
changes of the analytes’ linear velocities, and thus should be minimized.
2.3.2 Square Capillary
To confirm the benefit of hydrodynamic focusing in the microfluidic flow cell, a square
capillary with no focusing was used as a flow device to test the operation of the TDI SFC using
fluorescent beads as biological cell models. The data obtained in each flow device are compared.
The differences of no focusing in a square capillary versus 1D focusing in a T-shaped microchip
flow cell are shown in Figure 2.8. More detailed data and COMSOL simulations are in Chapter
4.
Figure 2.8 Flow devices used in this thesis. The T-shaped microfluidic flow device is capable of
providing 1D flow focusing of the analytes, improving the uniformity of the analytes’ linear
velocities for optimal synchronization with the TDI CCD’s parallel shift rate.
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2.4 Conclusion
Leukemia is a serious malignancy that necessitates more sensitive detection methods that
are able to use PB samples instead of BM samples to facilitate more frequent monitoring of
disease recurrence, which can result in a better outcome for patients, especially those with acute
type leukemias.2 Our group has previously reported the detection of rare leukemic cells in acute
myeloid leukemia (AML) patients’ blood samples using affinity isolation through curvilinear
microfluidic chips and cell immunophenotyping via fluorescence microscopy.30 Despite the
heterogeneity of the leukemia-associated cell immunophenotypes in AML patients, our
microfluidic assay improved the sensitivity of leukemic blast detection from 10-3 – 10-4 using
conventional flow cytometry and 1-5% using morphology to 10-6 (leukemic cells/WBCs).13,20,30
However, immunophenotyping the chip-isolated leukemic cells by fluorescence
microscopy often required long and laborious processing with various data analysis algorithms to
generate reliable results and therefore can be throughput-inefficient. Flow cytometry is another
immunophenotyping method with higher throughput than fluorescence microscopy and is often
used to analyze leukemic cells from leukemia patients 35; it can process cells rapidly (104 cells/s),
but requires a large number of cells to generate statistically reliable results; and due to the
transient nature of the cells within the sampling zone, it becomes difficult to detect cells with low
antigen expression levels. Additionally, because traditional flow cytometers are bandpass filter-
based, they only acquire data at certain wavelengths instead of acquiring the entire emission
spectra, possibly resulting in bias and/or misclassification, especially when there are only limited
numbers of cells or the cells are generating considerable autofluorescence due to disease
progression or treatment. Therefore, for chip-isolated cells that are usually in the range of 10,000
or below, traditional flow cytometry is not compatible for accurate cell immunophenotyping. To
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address the issues between the time-consuming fluorescence microscopy and the cell number-
demanding flow cytometry, we will report on a spectral flow cytometer with time delayed
integration (TDI SFC).
2.5 Summary of Subsequent Chapters
Chapter 3 describes the detection and analysis of glycopeptides by a semi-targeted data
acquisition strategy, the inclusion approach, as opposed to the top 10 approach in the commonly
employed DDA mode during MS/MS experiments. In this study, to facilitate the inclusion
approach, a publicly accessible software tool GlycoPep MassList is developed to aid in
generating large numbers of glycopeptide masses. To validate the advantages of the inclusion
approach, human IgG, an important endogenous glycoprotein of the immune system, is digested
by trypsin and the resulting peptides and glycopeptides are analyzed by mass spectrometry using
inclusion and top 10. A more complex sample, a mixture of bovine fetuin and chicken avidin is
also tested with inclusion and top 10. The data are manually analyzed and the glycopeptide
coverages are summarized to demonstrate the value of the software tool GlycoPep MassList and
the merits of the inclusion approach as a MS/MS data acquisition strategy.
Chapter 4 introduces the characterization of an in-house developed time delayed
integration spectral flow cytometer (TDI SFC) designed for enumerating and
immunophenotyping microfluidic chip-isolated cells, in particular chip-affinity selected
leukemic cells. In this study, the TDI SFC is first characterized using fluorescent calibration
beads. The field of view and readout time of the TDI SFC are measured to find out the
theoretical ideal linear velocity of the analytes for optimal clocking with respect to the TDI CCD.
Because TDI depends on the synchronization of the linear velocity of the fluorescent particles
and the readout rate of the TDI CCD, fluorescent calibration beads are used as cell models to
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discover the optimal flow rates for ideal synchronization. COMSOL simulations are carried out
to confirm the agreement of the theoretical results and experimental results. Subsequently,
optimizations in various aspects, such as using higher power light source, applying a higher
magnification objective and increasing the total full frame integration time, are performed to
improve the fluorescence intensity and SNR. The detection efficiency and throughput were also
evaluated by comparing the data from our TDI SFC with the data from a commercial flow
cytometer.
Chapter 5 details the validation of the TDI SFC by successfully detecting stained
leukemic cell lines. The stained B cell acute lymphoblastic leukemia (B-ALL) cells, SUP-B15
cell lines, were used as CLC models to validate the application of the TDI SFC. The detection
markers consisted of a nuclear stain 7-aminoactinomycine D (7-AAD) and anti-Terminal-
deoxynucleotidyl Transferase (TdT) FITC. 7-AAD as a nuclear stain is used to make sure that
the events detected are truly from a cell and not from an interferent. Terminal-deoxynucleotidyl
transferase (TdT) is a B-ALL marker that is positively expressed in ~90% of ALL patients and a
commonly included marker for B-ALL leukemic cells detection by flow cytometry. Thus, it is
used as another detection marker. To perform spectral deconvolution, unmixing algorithms were
developed and optimized to resolve each marker’s fluorescence emission from to total emission
spectra acquired by the TDI SFC.
Chapter 6 outlines the future work that can potentially push the TDI SFC into new areas
of application with better performance compared to traditional flow cytometry and also improve
the performance of the reported TDI SFC. A critical aspect will be replacing the one dimensional
(1D) focusing microchip reported in Chapter 4 with a two dimensional (2D) focusing chip. The
2D focusing is capable of confining the cells into a very small cross section at the center of the
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channel. Therefore, it results in two main advantages. First, with 2D focusing the cells’ linear
velocities will be much more uniform than that in the T-shaped microfluidic flow cell with 1D
focusing, leading to much higher percentage of the cells with velocities that more closely match
the parallel shift rate of the TDI CCD. Second, the variance of the fluorescence signal from the
cells is primarily due to the marker expression level differences on the cells instead of the
positional difference of the cells at the microfluidic channel. Another modification that can
improve the performance of the system is to improve the CCD camera’s frame rate. If the frame
rate is faster, the cells can move faster in the microfluidic channel. This can not only improve the
throughput and make data collection more time-efficient, but also can reduce the probability of
the cells’ sedimentation in the fluidic system and obtain higher detection efficiency.
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CHAPTER III
GlycoPep MassList: Software to Generate Massive Inclusion Lists
for Glycopeptide Analyses
This work has been published by the journal Analytical and Bioanalytical Chemistry, with
reprint permission from the journal.
3.1 Introduction
Protein glycosylation is one of the most significant and fundamental post translational
modifications (PTMs) in nature.1 Glycosylation, like other PTMs, leads to the increased
diversification of protein structures and functions.2,3 The most common type of glycosylation, N-
linked glycosylation, occurs when the glycan is appended to the side chain of a asparagine
following the consensus sequence N-X-T/S, where X is any amino acid except proline.4 The
glycans appended at N-linked glycosylation sites mainly depend on the glycosyltransferase
enzyme availability and the microenvironment of the protein.5,6 The glycans play crucial roles in
a variety of biological processes including protein folding7, protein stabilization8, immune
response9, cell-environment communication10, and fertilization11. Many times, a particular glycan
profile is essential for the glycoprotein to function optimally.9 Alterations in the glycosylation
site, the extent of glycosylation, or the glycosylation profile are associated with a broad spectrum
of diseases12,13, ranging from rheumatoid arthritis14, Alzheimer’s disease15 to prostate16,
colorectal17 and breast cancer18. The identification of abnormally glycosylated proteins has
biomedical value because these features may serve as disease biomarkers.19-21 Therefore, in order
to gain more understanding in protein structure-function correlations and/or to exploit
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glycoproteins in biomarker discovery and disease diagnosis, one must be able to characterize the
glycosylation on N-linked proteins in an efficient manner.
Analysis of N-linked glycosylation can be done in a variety of ways, but often
researchers prefer to obtain the relevant information by analyses of proteolyzed
glycopeptides.22,23 In these experiments, the glycans remain linked to the site on the protein at
which they reside. In this case, the most common workflow involves tryptic digestion of the
protein, followed by LC-MS/MS analysis.24 Past research has demonstrated that in all but the
simplest cases, high resolution MS data are not sufficient to accurately identify glycopeptides.25
MS/MS is necessary to distinguish among various possible glycopeptide assignments for any
given MS peak.22,25 The MS/MS data can be used to determine the glycosylated protein sequence,
the glycosylation site, and the glycan composition.26,27
Collision induced dissociation (CID) is the most commonly used dissociation method for
glycopeptide analysis. One of its key advantages is its rapid duty cycle, allowing for data
acquisition on multiple co-eluting glycopeptides. However, glycopeptide analysis by CID is still
challenging, due to glycopeptides’ intrinsic low abundance. The macroheterogeneity which
comes from the difference of glycosylation site occupancy, and the microheterogeneity, which
results from the attachment of different glycans to one specific glycosylation site, render each
glycoform in a low copy number after proteolysis.28-30 Consequently, the most commonly used
MS/MS data-dependent acquisition (DDA) mode, where the most intense ions in the full MS
scan are selected for MS/MS, is not optimal for glycopeptide analyses because the high-abundant
precursor ions, which are often non-glycosylated peptides, are redundantly selected for MS/MS,
while the relatively low abundant glycopeptide ions may not trigger MS/MS, even if dynamic
exclusion is enabled.31 This experiment results in missed detection of glycopeptides and limited
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glycopeptide coverage, particularly when the sample has a complex matrix that brings high
background corresponding to non-glycosylated peptides.
A significant thrust of research in the area of glycopeptide analysis is, therefore, focusing
on the problem of enhancing the number of glycopeptides selected for MS/MS analysis in a
given sample. Sample preparation strategies, particularly glycopeptide enrichment, can
contribute to this solution by reducing the number of non-glycosylated peptides present in the
sample.32,33 New MS methods are also needed. One such strategy that has not yet been readily
adopted, but which theoretically could benefit the field, is a targeted analysis approach, taking
advantage of instruments’ ability to selectively conduct MS/MS on ions preloaded onto an
inclusion list.
Targeted data acquisition is a well-known strategy that has been used to alleviate the
biased ion selection inherent in DDA strategies in other fields, but it has not yet been commonly
applied to the field of glycoproteomics. The proteomics field has already demonstrated that
targeted data acquisition consumes fewer MS/MS scans on peptides that have high abundance
but are not of interest to the investigators.31 Targeted data acquisition strategies have been
successfully employed to study arginine methylation34, for example. The method, however, does
not readily transfer to the field of glycopeptide analysis, primarily because the glycan component
on the glycopeptide may be any one of hundreds of different masses. With such a tremendous
variety of glycans, it would be a time-consuming process to generate an inclusion glycopeptide
mass list every time a new glycoprotein is to be studied.
At least two groups have shown that using inclusions lists for glycopeptide analysis is a
promising approach. Yin Wu and colleagues developed a software-based strategy that adds
putative glycopeptide ions to an inclusion list for targeted MS/MS experiments.35 Their strategy
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relies on using the software GlycoPID to identify glycopeptides in untargeted manner first, then
additional ions in the high resolution spectra that may also be glycopeptides are added to an
inclusion list on a second, or third, or fourth round of experiments. This iterative fashion of
targeted MS/MS experiment clearly achieves enhanced coverage, compared to a single round of
untargeted experiments. The disadvantage of this approach is that multiple LC-MS/MS analyses
are required for each sample, and the GlycoPID tool must be used for the glycopeptide
assignments. GlycoPID is just one of many emerging bioinformatics platforms used for the
glycopeptide analysis, and often users may want to use different software (or even manual
analysis) to analyze their data. More recently, Froehlich and coworkers developed a mass defect
classifier that tentatively identifies potential glycopeptide ions in a first-pass LC-MS analysis,
and those ions could then be loaded onto an inclusion list during a re-analysis experiment.36 This
approach may be advantageous to the one built into GlycoPID, because no glycopeptide
compositions need to be assigned initially, and users can select any glycopeptide analysis
software they choose. This approach still requires an initial data acquisition phase, followed by
data analysis, followed by at least one more round of data acquisition.
In the work described herein, we provide a software tool designed to generate inclusion
lists for glycopeptides prior to any data acquisition steps. This software allows users to target
glycopeptides for MS/MS in a single round of experiments, reducing the sample requirements
and analysis time that results from doing multiple LC-MS injections. Any glycopeptide analysis
software can be used in conjunction with this tool to interpret the data. The software was
designed such that users could input any protein sequence of interest, and the peptides containing
N-linked glycosylation sites are coupled to an on-board glycan library, which can be customized
by the user, producing appropriate glycopeptide masses that can easily be uploaded into an
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inclusion list for MS/MS analyses. A preliminary demonstration of the potential application of
the software is described, along with some strategies that can potentially maximize the benefit of
identifying glycopeptides using this approach.
3.2 Materials and Methods
3.2.1 Materials and Reagents
Fetuin from fetal bovine serum, avidin from chicken egg white, and human serum IgG
were purchased from Sigma Aldrich (St. Louis, MO). Sequencing grade trypsin was obtained
from Promega (Madison, WI). HPLC grade acetonitrile and methanol, ammonium bicarbonate,
urea, guanidine hydrochloride (GdnHCl), dithiothreitol (DTT), iodoacetamide (IAM), and formic
acid were purchased from Sigma Aldrich (St. Louis, MO). All the reagents were of analytical
grade or better and were used without further purification.
3.2.2 Protein Digestion
Between 100 and 400 μg bovine fetuin or chicken avidin was dissolved in 50 mM
ammonium bicarbonate buffer (pH 8.0) and denatured by adding urea until the concentration
reached 6 M. The disulfides of the denatured proteins were reduced by DTT, which was added to
reach a final concentration of 10 mM. The DTT reacted for one hour at room temperature. IAM
was added to alkylate the disulfides; its final concentration was 25 mM. It reacted for one hour in
the dark at room temperature. The excess IAM was quenched by DTT (final concentration 30
mM) for half an hour at room temperature. Subsequently, the protein solutions were diluted with
50 mM ammonium bicarbonate buffer to reach a urea concentration of 1 M, prior to incubation
with trypsin (trypsin/protein, 1/30) at 37°C for 20 hours.
Human IgG, 100 μg, was dissolved in 50 mM ammonium bicarbonate buffer (pH 8.0)
and was denatured by the addition of GdnHCl until the solution concentration reached 6 M. The
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reduction, alkylation and quenching of excess IAM were the same as described above. The
resulting protein solution was buffer exchanged with 50 mM ammonium bicarbonate buffer for
two times to remove most of the GdnHCl. The buffer exchanged solution was made to a final
volume of 100 μL before incubation with trypsin at a trypsin/protein ratio of 1/30 at 37°C for 20
hours. Finally, the digestion was stopped by adding formic acid with a formic acid/digestion
solution ratio of 1/100. Each digested protein sample was aliquoted and stored at -20°C until it
was analyzed.
3.2.3 LCMS
Glycoprotein samples were separated on a reverse phase C18 capillary column (300 μm
i.d. × 5 cm, 100 Å pore size, Micro-Tech, Vista, CA) online using a Waters Acquity high
performance liquid chromatography (Milford, MA) prior to mass spectrometric analysis in an
LTQ Orbitrap Velos Pro hybrid mass spectrometer (Thermo Scientific, San Jose, CA). About 5
μL of the diluted digestion sample was injected with a mobile phase flow rate of 10 μL/min and
gradient elution. Mobile phase A consisted of water with 0.1% formic acid, and mobile phase B
consisted of acetonitrile with 0.1% formic acid. For human IgG, the HPLC gradient was as
follows: 5% B for 3 min, 5% to 40% B in 37 min, 40% to 90% B in 10 min, 90% B for 10 min,
90% to 5% B in 10 min, and 5% B for 10 min. For the mixture of fetuin and avidin, the same
solvents were used, and the HPLC gradient was: 2% B for 5 min, 2% to 45% B in 50 min, 45%
to 90% B in 8 min, 90% B for 10 min, 90% to 2% B in 10 min, and 2% B for 10 min. A wash
and blank run were applied between each sample to minimize sample carryover.
For mass spectrometric analysis, the positive ion mode was utilized with an ESI source
voltage of 3 kV and capillary temperature of 250°C. The MS full scans were at a resolution of
30,000 (for m/z 400). The CID MS/MS scans were collected in a linear ion trap in a data-
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dependent fashion. The ten most intense precursor ions from inclusion lists (when applicable) or
from the MS preview scan were isolated for CID. The parent mass widths for inclusion lists were
±10 ppm. After being selected for MS/MS, with a repeat count of 2 within a repeat duration of
50 s, the precursor ion was dynamically excluded for 180 s. The FTMS had an automatic gain
control (AGC) target value of 5e5 with a maximum injection time of 400 ms. For CID MS/MS,
the AGC was set with a target value of 104 and a maximum injection time of 50 ms. The
isolation mass window for selecting a precursor ion was 2 Da. Normalized collision energy of
30% was applied with an activation time of 10 ms. The MS and CID MS/MS data were manually
interpreted to obtain the glycopeptide coverage.
3.2.4 Software Overview
GlycoPep MassList is a free publicly accessible software tool designed for generation of
inclusion lists in targeted analysis of glycopeptides. The theoretical glycopeptide mass
computation can be easily performed by specifying the protein sequence, glycan library, charge
state, mass range, number of missed cleavages, and the isotope preferred by the users. The
software was written in Java (JDK7) and can be run on Windows 7 or newer version of Windows.
Java Runtime Environment 7 (JRE 7) is recommended to successfully run the software.
3.2.5 Glycan Library of the Software
To rapidly and effectively generate potential glycopeptide masses, a default glycan
library, consisting of 340 glycans, was integrated into the software. These glycans include high
mannose, hybrid, and complex glycans that are found in nature. The glycans were categorized
into five groups: 1. high mannose and pauci-mannose glycans; 2. complex or hybrid glycans
without sialic acids; 3. glycans with NeuAc; 4. glycans with NeuGc 5. glycans with [PO3] or
[SO3]. For the sialylated glycans, those containing NeuAc were separated from the ones
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containing NeuGc because NeuGc cannot be biosynthesized by humans 37. Thus, when analyzing
human derived glycoproteins, NeuGc-containing glycans are not present and do not need to be
considered.
Although the native glycan library is extensive and contains biologically relevant glycans
from a wide range of sources, it does not cover all the N glycans that are present in nature.
Therefore, the software was designed so that users can upload their own glycan libraries. The
users can also use one or multiple groups of glycans from the software together with their own
glycan libraries.
3.2.6 Implementation of the Software for the Experiments Described Here
The glycopeptide m/z’s that were selected for inclusion list experiments in the examples
shown herein were generated using these procedures: (1) No missed cleavages were calculated.
(2) It was assumed that the glycopeptide did not have any post translational modification other
than glycosylation. (3) The glycopeptide m/z’s from charge state +2 to +8 were considered. (4)
The glycopeptide m/z’s in the range of m/z 800 to 2000 were selected. Procedures (1) and (2)
were used to reduce the number of entries on inclusion list, yet keep the valuable entries. This
increased the specificity of ion selection and decreased the probability of random matches
between the masses on the list and the masses detected from the sample background that did not
correspond to glycopeptide ions. While we have included the option to calculate glycopeptides
with miscleavages, initial testing has shown that this option does not increase the number of
unique glycopeptides subjected to MS/MS experiments, particularly when the protein is
optimally digested initially. Procedure (3) was applied so that the glycopeptides with a variety of
sizes could be identified using one search. The mass range (m/z 800 to 2000) was selected based
on our experience on MS-based glycopeptide analysis: Almost all glycopeptides are observed in
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at least one charge state above m/z 800. While these procedures may not be universal best
practices, depending on the experiment to be performed, they demonstrated themselves to be
advantageous in numerous test cases we ran. In addition to these procedures, we observed that it
is worthwhile to select the precursor ion type carefully. The higher abundance 13C mass of the
glycopeptide was used instead of the lower abundance monoisotopic mass. In the experiments
using human IgG, the first 13C masses were used. In the experiments using a fetuin and avidin
mixture, the second 13C masses were used. These isotopes were selected based on the size of the
peptide. The larger the peptide, the more likely that a higher isotope will be the most abundant
peak in the isotopic cluster.
3.3 Results and Discussion
3.3.1 Software Development and Implementation
The software described herein is a free tool to calculate theoretical glycopeptide masses
and generate inclusion lists for targeted data acquisition on glycopeptides. A screenshot of the
user interface is shown in Figure 3.1. In order to calculate the glycopeptide mass, users input the
required information such as protein sequence, glycan library, number of missed cleavages (up to
3), charge state (from 1 to 8) and mass range (400 to 2000). The users can also choose to
calculate monoisotopic mass or the mass of one of the higher isotopes (up to the third 13C mass),
depending on the glycopeptide of interest.
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Figure 3.1 User interface for GlycoPep MassList. Users input the protein sequence, glycan
library, charge state, mass range, number of missed cleavages, and select the mass (monoisotopic
mass or 13C mass) to be calculated. In silico tryptic digestion is then performed on the protein,
and all the potential glycosylated peptides are reported by the software. The output is displayed
under Result: Inclusion List. One or multiple groups of glycans can be selected, or custom
glycan libraries can be uploaded, or a combination of manually input libraries and those in the
database can be used.
After the appropriate data are input, the software executes an in silico tryptic digestion on
the protein sequence, and all the peptides that have a potential N-linked glycosylation site
(NXS/T, X≠P) are extracted. In the current form of the software, cysteines are, by default,
considered to be alkylated by iodoacetamide (IAM), a widely used alkylation reagent in protein
digestion. Next, theoretical glycopeptide m/z values, based on all the combinations of the
glycosylated peptides and the user-specified glycans, are computed. The results are displayed
under “Result: Inclusion List”. Each theoretical glycopeptide appears on one line, with the
glycopeptide composition shown on the left and m/z on the right.
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After the software was developed and carefully tested, two sets of CID experiments were
conducted, in order to compare the performance of targeted data acquisition strategy (with
inclusion lists) and the conventionally used data dependent acquisition strategy (without
inclusion lists), where the top 10 most intense precursor ions are selected for MS/ MS. The two
experiments are henceforth referred to as the “inclusion” experiment, or the “top 10” experiment,
respectively.
3.3.2 Analysis of Human IgG
Plasma-derived human IgG is an important class of antibody.38-40 The glycosylation site
located at the Fc region has an effect on the interaction of IgG with Fc gamma receptor (FcγR) 41.
Aberrant glycosylation on this site is related to diseases.42 For example, a lower degree of
galactosylation was observed in patients with rheumatoid arthritis.8 When comparing the IgG
glycosylation profiles of diseased and healthy states, one must identify all glycoforms present,
otherwise the glycosylation differences, due to the samples themselves, will not be known. IgG
is also a very important recombinantly expressed biotherapeutic.43 The efficacy and side effect of
IgG therapeutics are closely related to their glycosylation.43,44 For instance, antibodies with high
mannose glycans are cleared faster in human serum.45 Glycans containing NeuGc can cause an
unwanted immune response.44 Thus, it is important to ensure the glycan profile fidelity across
different expression vehicles, conditions, and batches.
Hence, human IgG was used to compare the efficiency of the new “inclusion List”
software and strategy, to the traditional, untargeted, top 10 approach. Utilizing the software for
the inclusion approach requires three steps: choosing an appropriate glycan library, building the
inclusion list, and then conducting the LC-MS experiment. Each step is elaborated upon, briefly,
here. When the software is used for other applications, a similar workflow should be followed.
54
An appropriate glycan list must be chosen. The N linked glycopeptides from IgG Fc
region mainly contain complex-type biantennary glycans. These glycans are mostly core-
fucosylated; they have up to two galactose residues; they may be sialylated and bisected by an N-
acetylglucosamine (GlcNAc) residue.46 We compiled a glycan library ideal for IgG analyses by
researching the literature associated with human IgG glycosylation.38-40,45,47 The glycan list for
these experiments contains 52 glycans, and it can be found in the SI Table 3.1. All these glycans
are either reported previously for IgG or are reasonable additional glycans that may be present,
based on the rules of glycotransferase processing.
After building the glycan library, which can now be used for any IgG experiment,
GlycoPep MassList was used to generate the inclusion masses for the targeted data acquisition.
The IgG protein sequence and the compiled glycan library for human IgG were uploaded to
obtain the theoretical glycopeptide masses. Since EEQYNSTYR and EEQFNSTFR
glycopeptides are commonly observed in tryptic digests of IgG, they were both included. To
compare the inclusion experiment with the commonly used top 10 experiment, LC-MS runs with
an inclusion list and without the inclusion list were performed back-to-back on the same day
using the same digested protein sample. In the inclusion experiment, an inclusion list populated
with the first 13C masses of the theoretical glycopeptides was imported into the instrument
software, while in the top10 experiment, no inclusion list was applied.
The resulting MS data are depicted in Figure 3.2. The tryptic glycopeptides
EEQYNSTYR and EEQFNSTFR eluted at about 6.5 min and 16.5 min, respectively. The elution
of EEQFNSTFR is indicated by a pink bar on the total ion chromatogram (TIC) in Figure 3.2a.
The MS data for this glycopeptide rich region of the chromatogram, containing multiple
glycopeptides from the EEQFNSTFR site is shown in Figure 3.2b. The high abundance
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glycopeptides in this spectrum, labeled with stars, were selected for CID in both the inclusion
and top 10 experiments, while the low abundance ones, labeled with triangles, were only selected
for CID in the inclusion experiment.
One glycopeptide identified only by inclusion but not top 10 is shown in Figure 3.2c.
This low abundance glycopeptide was only observed in the +2 charge state in the high resolution
MS data. Because of its relatively low abundance, this precursor ion was not selected for CID in
the top 10 experiment. Nevertheless, in the inclusion experiment, this ion was selected for CID.
As clearly shown in Figure 3.2c, the CID data still produced sufficient data to confirm the
glycopeptide assignment.
All the detected glycopeptides, selected by inclusion and/or top 10, were identified. The
data for each experiment are fully reported in SI Table 3.2. Most of the detected glycopeptides
from each site were core fucosylated. A minor portion of them were sialylated. The sialylated
glycopeptides eluted about one minute later than the non-sialylated ones, which agreed with
previous reports.39
The glycopeptide coverage summary for the inclusion and top 10 experiments is shown
in Figure 3.3. It is worth noting from Figure 3a that all the unique glycopeptides observed in the
high resolution spectrum with ion intensities more than 200 counts (the signal threshold for CID)
were selected for CID by the inclusion experiment. Additionally, inclusion outperformed top 10
by selecting seven more unique glycopeptides for CID, which contributed to a notable 39%
higher glycopeptide coverage.
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Figure 3.2 Example data from inclusion experiment. a Ion chromatogram of the IgG
glycoprotein digest, indicating where one of the peptides, EEQFNSTFR, elutes. b MS data for
the highlighted region in a. Stars, Glycopeptide selected for MS/MS by inclusion and top 10.
Triangles, Glycopeptides selected for MS/MS only by inclusion but not by Top10. c The CID
spectrum of a glycopeptide that was only selected by inclusion. The ion, m/z 1281.52,
corresponds to EEQFNSTFR+[Hex]4[HexNAc]3Fuc]1. Its composition can be confirmed by the
product ions in c. Blue squares, N-acetylhexosamines. Red triangle, fucose. Green and yellow
circles, hexoses.
The number of unique glycopeptides from each site selected for CID by inclusion and top
10 are shown in Figure 3.3b. Inclusion showed higher efficiency than top 10 on both
glycosylated peptides analyzed. The inclusion approach was especially advantageous on the site,
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EEQFNSTFR. In this case, top 10 selected only 8 unique glycopeptides for MS/MS, while
inclusion selected 13, showing a prominent advantage of 62% higher coverage. Although the
advantage was narrower on site, EEQYNSTYR, where 12 unique glycopeptides were triggered
CID by inclusion, and 10 by top 10, inclusion still showed 20% higher coverage.
Figure 3.3 IgG glycopeptides selected for CID by inclusion or top 10 experiments. a
Comparison of the total number of unique glycopeptides observed in the high resolution MS data
vs. those that were selected for CID during inclusion or top 10. Inclusion got 100% coverage and
selected seven more glycopeptides (39% more) than top 10. b The number of unique
glycopeptides from each site selected for MS/MS by inclusion and top 10. P1=EEQYNSTYR.
P2=EEQFNSTFR. For P2, a greater advantage was observed because the chromatogram had
more co-eluting interferents in this region that were selected for MS/MS by the top 10
experiment
The reason the inclusion approach was more advantageous on one of these two sites is
likely related to what else was co-eluting when the glycopeptides were being selected for CID.
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The glycopeptide, EEQYNSTYR, eluted at about 6.5 min, while there was a limited number of
non-glycosylated peptides co-eluting. The limited background from the non-glycosylated
peptides allowed the traditional top 10 approach to pick up almost all of the glycopeptides for
CID. The other glycopeptide, EEQFNSTFR, eluted at about 16.5 min, when the non-
glycosylated peptides also started eluting. As the non-glycosylated peptides both outnumbered
the glycopeptides, and were present in higher abundance, the efficiency of the traditional top10
experiment was substantially reduced: more duty cycle was wasted on the background peaks
instead of glycopeptide peaks. On the contrary, the inclusion experiment was able to prioritize
the duty cycle on the highly possible glycopeptide peaks pre-assigned on the inclusion list. This
resulted in the inclusion approach working especially well for the EEQFNSTFR peptide,
compared to EEQYNSTYR.
3.3.3 Targeted Data Analysis of Fetuin/Avidin Mixture
To further test the utility of the use of targeted inclusion lists for glycopeptide, we used a
more complex sample involving two proteins with multiple glycosylation sites. More specifically,
a mixture that had 15 pmol fetuin and 1.7 pmol avidin was used. This glycoprotein mixture was
chosen for two reasons. First, these well studied glycoproteins have very different glycosylation
profiles. Fetuin has complex type glycans, while avidin has mainly high mannose and hybrid
type glycans.48 Hence, the glycan library for this experiment incorporated all the three types of
glycans. Secondly, the avidin protein was purposely added in a low abundance, since identifying
low-abundant glycopeptides is a particularly large challenge in the field of glycoproteomics. We
were interested in determining how the inclusion and top 10 strategies compared when the
glycoprotein of interest was a small component of the overall sample.
59
In this experiment, the glycan library was designed differently from the first set of
experiments as well. Unlike the case of human IgG, where most glycans of the glycan library are
highly possible oligosaccharides for human IgG, most glycans in this library did not correspond
to the ones in the glycoprotein sample used. Consequently, most m/z’s on the inclusion list did
not correspond to the glycopeptide m/z’s in the sample. The goal of this set of experiments was
to begin to understand the impact of using large inclusion lists; could these lists still select more
glycopeptide ions for MS/MS than the commonly used top 10 approach?
The glycopeptide coverage summary for the inclusion and top 10 experiments is shown
in Figure 3.4. Figure 3.4a summarizes the complete glycopeptide coverage for all the
glycoforms at all the glycosylation sites, and, as expected, the inclusion approach was superior to
the top 10 experiment in selecting more glycopeptide ions for CID. Similar to the results of
human IgG, all the 27 unique glycopeptides observed in the high resolution mass data that had
ion intensities above the signal threshold for CID were selected by inclusion for MS/MS
experiments, while only 21 unique peptides were selected by top 10. This difference corresponds
to a 29% increase in coverage.
To understand the circumstances that benefit the inclusion approach, we also compared
the results for each protein separately. These are displayed in Figure 3.4b. In this figure, one can
clearly see that the inclusion approach was most beneficial for the more complex, lower-
abundant protein, avidin. For avidin, 16 unique glycopeptides were selected for MS/MS in
inclusion, compared to 12 unique ones for top 10, representing a 33% higher coverage. For fetuin,
inclusion was still superior, but the gain was smaller. Here, inclusion vs. top 10 resulted in 11
unique glycopeptides vs. 9 unique glycopeptides, a 22% higher coverage.
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Figure 3.4 Result summary from the fetuin/avidin mixture. a All the unique glycopeptides
observed in the high resolution spectrum were selected for MS/MS by inclusion. Inclusion had
six more unique glycopeptides (29% more) selected for MS/MS than Top10. b The number of
unique glycopeptides from each protein selected for MS/MS by inclusion and top 10. The
inclusion approach was most efficacious for avidin because the top 10 experiments were less
effective when many glycopeptides were present in a high background.
The results for the fetuin/avidin experiments are consistent with those from IgG. When
glycopeptides are present in lower abundance, as is the case in the avidin experiment, or when
other non-glycosylated peptides are co-eluting, as is the case in the IgG experiment, the inclusion
approach shows its greatest benefit. These findings are not terribly surprising; in fact, we fully
expected this to be the case because top 10 experiments are well-known to leave out MS/MS data
on low-abundant species. What is somewhat surprising is that the inclusion approach worked
much better, even on relatively simple samples. These findings suggest that inclusion approach
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will show an even greater benefit when challenged with more complex samples, such as low-
abundant glycopeptides present in high background of interfering ions.
For the experiments described here, the number of ions added to the inclusion list ranged
between 233 ions for the IgG experiments and 1507 ions for the experiments where both fetuin
and avidin were simultaneously examined. Clearly, the large number of ions on the inclusion list,
compared with other more targeted approaches, did not limit the instrument’s ability to pick all
the relevant glycopeptides for MS/MS analysis. One key reason for the success of these
experiments is the fact that we used a relatively small mass width (10 ppm) for the ions on the
inclusion list. The mass width (Da) multiplied by the number of ions on the inclusion list roughly
determines the amount of spectral space that is being queried in a given experiment. For example,
with 1500 ions on the inclusion list, and a selection criterion of ±10 ppm, the spectral space
being queried is approximately 0.03 Da multiplied by 1500 ions, or 45 Da, in the range of m/z
800–2000. In other words, about 4 % of the available spectral points between m/z 800 and 2000
are being queried under these circumstances. Either increasing the mass tolerance for the ions on
the inclusion list (to larger than 10 ppm) or increasing the number of ions queried, increases the
percentage of the spectral space being queried; therefore, these changes can decrease the value of
using an inclusion list. The instrument control software on the mass spectrometer used for these
studies limits the inclusion list to 2000 ions, so there is also a fixed limit to the number of ions
that can be queried.
3.4 Conclusion
MS/MS data is necessary to accurately identify glycopeptides. Nonetheless, due to the
relatively low signals of glycopeptides in MS scans, many glycopeptide ions are not selected for
MS/MS during a single DDA experiment. This problem prompted us to develop the software
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GlycoPep MassList to facilitate the inclusion experiments for glycopeptide analysis. This
software tool can rapidly generate inclusion lists for glycoproteins, so that targeted glycopeptide
analyses can be performed.
To test the application of this software and the inclusion strategy, two experiments were
conducted. In both experiments, the inclusion strategy outperformed the traditional top 10
experiment by substantial margins. Furthermore, the experiments herein demonstrated that the
inclusion approach is particularly advantageous when the glycoprotein of interest is present in
low abundance, when it co-elutes with many non-glycosylated peptides, and/or when a variety of
glycoforms are appended at the same glycosylation site. While the software was tested in several
experiments where CID data were collected, the tool is agnostic towards the type of dissociation
method used, and it could readily be applied to trigger ETD or HCD experiments as well.





1 Glycan library used in targeted analysis of human IgG Fc N-linked
glycopeptides
2 All the detected glycopeptides from human IgG Fc region by each strategy















































































































SI table 3.2 All the detected glycopeptides from human IgG Fc region and whether each













@ Hex3HexNAc3Fuc1 +2 1215.9869 1215.9844 2 yes no
@ Hex3HexNAc4 +2 1244.4976 1244.4960 1 yes no
+3 830.0009 829.9995 2 yes no
Hex3HexNAc4Fuc1 +2 1317.5266 1317.5242 2 yes yes
+3 878.6868 878.6857 1 yes yes
Hex4HexNAc4 +2 1325.5240 1325.5221 1 yes yes
+3 884.0185 884.0164 2 yes yes
Hex4HexNAc4Fuc1 +2 1398.5530 1398.5501 2 yes yes
+3 932.7044 932.7034 1 yes yes
Hex5HexNAc4 +2 1406.5504 1406.5447 4 yes no
+3 938.0361 938.0347 1 yes yes
Hex3HexNAc5Fuc1 +2 1419.0663 1419.0647 1 yes no
+3 946.3799 946.3797 0 yes yes
Hex5HexNAc4Fuc1 +2 1479.5794 1479.5771 2 no yes
+3 986.7220 986.7215 1 yes yes
Hex4HexNAc5Fuc1 +2 1500.0927 1500.0895 2 no no
+3 1000.3976 1000.3976 0 yes yes
Hex4HexNAc4NeuNAc1Fuc1 +2 1544.1007 1544.0983 2 no no
+3 1029.7362 1029.7351 1 yes yes
Hex5HexNAc5Fuc1 +2 1581.1191 1581.1152 2 no no
+3 1054.4152 1054.4142 1 yes no
Hex5HexNAc4NeuNAc1Fuc1 +2 1625.1271 1625.1249 1 no no
+3 1083.7538 1083.7498 4 yes yes
EEQFNSTFR
Hex3HexNAc3Fuc1 +2 1199.9920 1199.9906 1 yes yes
@ Hex3HexNAc4 +2 1228.5027 1228.5028 0 yes no
+3 819.3376 819.3318 7 no no
@ Hex4HexNAc3Fuc1 +2 1281.0184 1281.0170 1 yes no
Hex3HexNAc4Fuc1 +2 1301.5317 1301.5293 2 yes yes
+3 868.0236 868.0219 2 yes yes
@ Hex4HexNAc4 +2 1309.5291 1309.5249 3 yes no
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+3 873.3552 873.3538 2 no no
Hex4HexNAc4Fuc1 +2 1382.5581 1382.5548 2 yes yes
+3 922.0412 922.0398 2 yes yes
@ Hex5HexNAc4 +2 1390.5556 1390.5475 6 yes no
+3 927.3728 927.3713 2 no no
Hex3HexNAc5Fuc1 +2 1403.0714 1403.0701 1 yes yes
+3 935.7167 935.7162 1 yes no
Hex5HexNAc4Fuc1 +2 1463.5845 1463.5808 3 no no
+3 976.0588 976.0574 1 yes yes
Hex4HexNAc5Fuc1 +2 1484.0978 1484.0966 1 no no
+3 989.7343 989.7338 1 yes yes
Hex4HexNAc4NeuNAc1Fuc1 +2 1528.1058 1528.1031 2 no no
+3 1019.0730 1019.0726 0 yes yes
@ Hex5HexNAc5Fuc1 +2 1565.1242 1565.1205 2 no no
+3 1043.7519 1043.7510 1 yes no
Hex5HexNAc4NeuNAc1Fuc1 +2 1609.1322 1609.1289 2 no no
+3 1073.0906 1073.0894 1 yes yes
@ indicates the unique glycopeptide that was selected for CID by TDA but not by DDA.
67
3.6 References
(1) Dwek, R. A. Chem Rev 1996, 96, 683-720.
(2) Deribe, Y. L.; Pawson, T.; Dikic, I. Nat Struct Mol Biol 2010, 17, 666-672.
(3) Raman, R.; Raguram, S.; Venkataraman, G.; Paulson, J. C.; Sasisekharan, R. Nat Methods
2005, 2, 817-824.
(4) Harvey, D. J. Expert Rev Proteomics 2005, 2, 87-101.
(5) Dell, A.; Morris, H. R. Science 2001, 291, 2351-2356.
(6) Go, E. P.; Rebecchi, K. R.; Dalpathado, D. S.; Bandu, M. L.; Zhang, Y.; Desaire, H. Anal
Chem 2007, 79, 1708-1713.
(7) Wormald, M. R.; Dwek, R. A. Structure 1999, 7, R155-R160.
(8) Nagae, M.; Yamaguchi, Y. Int. J. Mol. Sci. 2012, 13, 8398-8429.
(9) Kolarich, D.; Lepenies, B.; Seeberger, P. H. Curr Opin Chem Biol 2012, 16, 214-220.
(10) Leymarie, N.; Griffin, P. J.; Jonscher, K.; Kolarich, D.; Orlando, R.; McComb, M.; Zaia, J.;
Aguilan, J.; Alley, W. R.; Altmann, F.; Ball, L. E.; Basumallick, L.; Bazemore-Walker, C. R.;
Behnken, H.; Blank, M. A.; Brown, K. J.; Bunz, S.-C.; Cairo, C. W.; Cipollo, J. F.; Daneshfar, R.,
et al. Molecular & Cellular Proteomics 2013, 12, 2935-2951.
(11) Grass, J.; Pabst, M.; Chang, M.; Wozny, M.; Altmann, F. Anal Bioanal Chem 2011, 400,
2427-2438.
(12) Fuster, M. M.; Esko, J. D. Nature Reviews Cancer 2005, 5, 526-542.
(13) Gornik, O.; Lauc, G. Disease Markers 2008, 25, 267-278.
(14) Saroha, A.; Biswas, S.; Chatterjee, B. P.; Das, H. R. Journal of chromatography. B,
Analytical technologies in the biomedical and life sciences 2011, 879, 1839-1843.
68
(15) Perdivara, I.; Deterding, L. J.; Cozma, C.; Tomer, K. B.; Przybylski, M. Glycobiology 2009,
19, 958-970.
(16) Fujimura, T.; Shinohara, Y.; Tissot, B.; Pang, P. C.; Kurogochi, M.; Saito, S.; Arai, Y.;
Sadilek, M.; Murayama, K.; Dell, A.; Nishimura, S.; Hakomori, S. I. Int J Cancer 2008, 122, 39-
49.
(17) Qiu, Y.; Patwa, T. H.; Xu, L.; Shedden, K.; Misek, D. E.; Tuck, M.; Jin, G.; Ruffin, M. T.;
Turgeon, D. K.; Synal, S.; Bresalier, R.; Marcon, N.; Brenner, D. E.; Lubman, D. M. Journal of
proteome research 2008, 7, 1693-1703.
(18) Drake, P. M.; Schilling, B.; Niles, R. K.; Prakobphol, A.; Li, B.; Jung, K.; Cho, W.; Braten,
M.; Inerowicz, H. D.; Williams, K.; Albertolle, M.; Held, J. M.; Iacovides, D.; Sorensen, D. J.;
Griffith, O. L.; Johansen, E.; Zawadzka, A. M.; Cusack, M. P.; Allen, S.; Gormley, M., et al. J.
Proteome Res. 2012, 11, 2508-2520.
(19) Stowell, S. R.; Ju, T.; Cummings, R. D. Annual Review of Pathology 2015, 10, 473-510.
(20) Ohtsubo, K.; Marth, J. D. Cell 2006, 126, 855-867.
(21) Dube, D. H.; Bertozzi, C. R. Nature Reviews Drug Discovery 2005, 4, 477-488.
(22) Goldberg, D.; Bern, M.; Parry, S.; Sutton-Smith, M.; Panico, M.; Morris, H. R.; Dell, A.
Journal of proteome research 2007, 6, 3995-4005.
(23) Desaire, H. Molecular & Cellular Proteomics 2013, 12, 893-901.
(24) Dalpathado, D. S.; Desaire, H. Analyst 2008, 133, 731-738.
(25) Desaire, H.; Hua, D. International Journal of Mass Spectrometry 2009, 287, 21-26.
(26) Mechref, Y. Current protocols in protein science / editorial board, John E. Coligan ... [et
al.] 2012, 12, 1-11.
(27) Quan, L.; Liu, M. Modern Chemistry & Applications, 2012, 1, e102.
69
(28) Aldredge, D.; An, H. J.; Tang, N.; Waddell, K.; Lebrilla, C. B. J. Proteome Res. 2012, 11,
1958-1968.
(29) Li, F.; Glinskii, O. V.; Glinsky, V. V. Proteomics 2013, 13, 341-354.
(30) Gagneux, P.; Varki, A. Glycobiology 1999, 9, 747-755.
(31) Schmidt, A.; Gehlenborg, N.; Bodenmiller, B.; Mueller, L. N.; Campbell, D.; Mueller, M.;
Aebersold, R.; Domon, B. Molecular & Cellular Proteomics 2008, 7, 2138-2150.
(32) Liu, T.; Qian, W.-J.; Gritsenko, M. A.; II, D. G. C.; Monroe, M. E.; Moore, R. J.; Smith, R.
D. Journal of proteome research 2005, 4, 2070-2080.
(33) Madera, M.; Mechref, Y.; Novotny, M. V. Analytical Chemistry 2005, 77, 4081-4090.
(34) Hart-Smith, G.; Low, J. K.; Erce, M. A.; Wilkins, M. R. J. Am. Soc. Mass Spectrom. 2012,
23, 1376-1389.
(35) Wu, Y.; Mechref, Y.; Klouckova, I.; Mayampurath, A.; Novotny, M. V.; Tang, H. Rapid
Communications in Mass Spectrometry 2010, 24, 965-972.
(36) Froehlich, J. W.; Dodds, E. D.; Wilhelm, M.; Serang, O.; Steen, J. A.; Lee, R. S.Molecular
& Cellular Proteomics 2013, mcp. M112. 025494.
(37) Varki, A. American journal of physical anthropology 2001, 116, 54-69.
(38) Stadlmann, J.; Pabst, M.; Kolarich, D.; Kunert, R.; Altmann, F. Proteomics 2008, 8, 2858-
2871.
(39) Selman, M. H. J.; Derks, R. J. E.; Bondt, A.; Palmblad, M.; Schoenmaker, B.; Koeleman, C.
A. M.; van de Geijn, F. E.; Dolhain, R. J. E. M.; Deelder, A. M.; Wuhrer, M. Journal of
Proteomics 2012, 75, 1318-1329.
(40) Zauner, G.; Selman, M. H. J.; Bondt, A.; Rombouts, Y.; Blank, D.; Deelder, A. M.; Wuhrer,
M. Molecular & cellular proteomics : MCP 2013, 12, 856–865.
70
(41) Vidarsson, G.; Dekkers, G.; Rispens, T. Front Immunol 2014, 5, 1-17.
(42) Shade, K.-T.; Anthony, R. Antibodies 2013, 2, 392-414.
(43) Jefferis, R. Nature reviews. Drug discovery 2009, 8, 226-234.
(44) Ghaderi, D.; Taylor, R. E.; Padler-Karavani, V.; Diaz, S.; Varki, A. Nature biotechnology
2010, 28, 863-867.
(45) Shah, B.; Jiang, X. G.; Chen, L.; Zhang, Z. J. Am. Soc. Mass Spectrom. 2014, 25, 999-1011.
(46) Reusch, D.; Haberger, M.; Maier, B.; Maier, M.; Kloseck, R.; Zimmermann, B.; Hook, M.;
Szabo, Z.; Tep, S.; Wegstein, J.; Alt, N.; Bulau, P.; Wuhrer, M. mAbs 2015, 7, 167-179.
(47) Wuhrer, M.; Stam, J. C.; van de Geijn, F. E.; Koeleman, C. A.; Verrips, C. T.; Dolhain, R. J.;
Hokke, C. H.; Deelder, A. M. Proteomics 2007, 7, 4070-4081.
(48) Oliver, R. W. A.; Greent, B. N.; Harvey, D. J. Biochem Soc Trans 1996, 24, 917-927.
71
CHAPTER IV
Characterizing Spectral Flow Cytometry with Time-Delayed
Integration (TDI SFC)
4.1 Introduction
Multi-parameter flow cytometry (MFC) is routinely used to characterize biological cells
for size, granularity, and protein expression. MFCs typically consist of a sheath flow system to
hydrodynamically align immunolabeled cells into a single file through an incident laser beam(s)
to provide high sampling efficiency and reduced variation in the signal due to the Gaussian
intensity profile of the excitation beam. Optical bandpass filters spectrally sort fluorescence into
relatively wide wavelength ranges (channels) that are transduced by photomultiplier tubes
(PMTs). Modern MFCs analyze 104 –105 cells/s on different fluorescence channels, enabling the
ability to process cells and identify unique subpopulations.1 However, there are intrinsic
limitations associated with processing low numbers of cells (<1,000) using MFC, such as the
need for establishing proper gating thresholds and compensation for channel cross-talk requiring
high (>20,000) cells used for the analysis. Further, with poor spectral resolution, which is
determined by the filter pass band, there is an inherent risk that biological “noise”, such as
abnormal autofluorescence from apoptotic cells,2,3 can produce misclassification.1 Improvements
in immunostaining classification by morphological localization of fluorescence signals, typically
restricted to microscopy, has been demonstrated using imaging flow cytometers (IFCs), such as
the ImageStream® that can acquire high-resolution, multispectral microscopy images of flowing
cells.4-8 Yet such systems are costly, and for routine clinical analysis, throughput is limited by
semi-automated data analysis.
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Spectral flow cytometry (SFC) shares the same hydrodynamic sheathing and laser
excitation strategy as MFC, but fluorescence emission is spectrally sorted onto a multichannel
detector, yielding higher spectral resolution than MFC. The emission spectrum can be
deconvoluted to quantify multiple fluorophores with considerable spectral overlap, including
autofluorescence signals.3,9-13 A commercial SFC instrument from Sony uses a series of prisms to
spectrally disperse fluorescence onto a 32-channel PMT array (500-800 nm, 9.4 nm
resolution).3,11 The Nolan lab pioneered the use of a diffraction grating spectrograph to disperse
fluorescence onto a CCD camera with high spectral resolution (0.4 nm/pixel).13 However, the
advantages provided by the spectrograph’s resolution are countered by the operating
characteristics of the CCD.10,12,13 The sensor’s duty cycle, the percent of time the sensor is
actively imaging, is low (~0.1%) due to short exposure times (~10 µs) and the extended readout
times (~10 ms).13 Thus, the probability that cells would not be detected is high, which can be
problematic for applications requiring the analysis of rare, low abundant cells.14
We present an SFC system operating in a time-delayed integration mode (TDI SFC).8,15
The optical schematic and photograph of the TDI SFC is shown in Figure 4.1. Cells are sheathed
into the cytometer’s field-of-view, where 488 nm laser excitation is coincident with the
observation zone of the collection optics. A spectrograph spectrally sorts the fluorescence along
the columns of the CCD pixel array, which is spatially confined to a few rows of the CCD (see
Figure 4.2). As the cell moves through the field-of-view, the image is shifted towards the serial
register at a rate that corresponds to the cell’s linear velocity (i.e., synchronization). As the cell
exits the field-of-view, the integrated emission spectrum is delivered for readout to the serial
register. As such, the shutter of the CCD sensor is rarely shut with the duty cycle determined by
the readout time of the CCD’s serial register.
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The coupling of SFC with TDI provides two main advantages. (i) Integration of the
signal in TDI mode along n pixel columns of the CCD improves the signal-to-noise by  
compared to a full frame readout in traditional SFC, which involves a snapshot mode of
operation.15 (ii) The shutter rarely closes (duty cycle approaches 100%) and multiple cells
occupying the field-of-view can be resolved by the short readout time. Thus, TDI SFC is
amenable for automated immunophenotyping of rare cells when the number of total cells
available is limited.
The TDI SFC system consisted of a microfluidic device providing 1D sheathing that was
interfaced with a custom optical system possessing 488 nm laser excitation, a collection
microscope objective, long pass filters to remove the Rayleigh scattered radiation and the laser
light, spectrograph, and a CCD sensor operated in a TDI mode. In this chapter, we optimized the
operation of this TDI SFC in terms of synchronization of the CCD TDI readout with the flow
velocity of biological cell models, in this case fluorescent polystyrene microbeads. The acquired
data was processed in MATLAB and statistically analyzed to discover the flow rates that gave
the best synchronization. Subsequently, we performed additional optimizations to improve upon
the SNR. We also investigated the dynamic range of the TDI SFC to discover the upper
throughput limit. All of these characterizations were critical and necessary to facilitate successful
follow-up experiments on real biological samples, such as circulating leukemia cells (CLCs)
isolated from the peripheral blood of leukemia patients or circulating tumor cells from epithelial
cancer patients.
4.2 Experimental Methods
4.2.1 Reagents and Materials
Microfluidic devices were fabricated using polymethylmethacrylate (PMMA) substrates
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(Plaskolite, Inc.) and PEEK tubing (0.020" ID, 1/32" OD and 0.007" ID, 1/32" OD, Idex Health
and Science) that was used to connect the input port of the microfluidic to a syringe pump.
Custom capillary connectors were Inner-Lok™ union capillary connectors (Polymicro
Technologies) and barbed socket Luer Lock™ fittings (3/32” ID, McMaster-Carr). Reagents
included: methanol-stabilized formaldehyde (37%), methanol-free formaldehyde (16%),
phosphate buffered saline (1X PBS, pH=7.4), and InSpeck™ Green fluorescent calibration kit
from Thermo Fisher Scientific; sucrose from Fluka; Micro-90®, reagent-grade isopropanol (IPA)
from Sigma-Aldrich; and anti-mouse Fc-specific Antibody Binding Capacity (ABC) beads from
Bangs Lab.
4.2.2 TDI SFC Optics
A 488 nm solid-state laser (54 mW, TEM00, 1/e2=1.3 mm, Vortran Laser Technology)
was used as the excitation source with the beam expanded using a 21.2× Keplerian beam
expander (planoconvex lenses, f=3 mm, f=63.5 mm, VIS 0° coated; Edmund Optics) or a 7.1×
Galilean beam expander (biconcave lens, f=-9 mm and planoconvex lens, f=63.5 mm, -A and
VIS 0° coated; Thorlabs and Edmund Optics, respectively). The beam was filtered using a 488/6
nm BrightLine® bandpass filter (Semrock), and the wings of the beam were cut using an
adjustable diaphragm (4.7 mm; Thorlabs) and focused (planoconvex lens, f=105 mm, -A coated;
Thorlabs) to the back focal plane of a microscope objective (10x Fluar, NA=0.5, WD=1.9 mm or
20x Fluar, NA=0.75, WD=0.6 mm; Zeiss). Emission was collected via epi-illumination, which
was filtered through a 495 nm BrightLine® dichroic beamsplitter and a 496/LP BrightLine®
edge filter (Semrock) and diverted to a CP200 spectrograph (Jovin Yvon) using silver turning
mirrors (Thorlabs). Fluorescence spectra were transduced using a Spec 10-100B back-
illuminated CCD (1340×100 pixels, 20 µm, Princeton Instruments; 16-bit dynamic range)
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controlled via a custom program built using the Scientific Instrument Tool Kit for LabVIEW®
(R Cubed Software). The system contained a focusing camera (MU503 RGB CMOS camera,
AmScope) inserted into the optical train via a kinematic beam turning cage cube and tube lens
(f=165 mm, -A coated; Thorlabs). All optics were assembled and mounted using cage cubes, lens
tubes, and micrometer translational stages (Thorlabs) and were enclosed in a light tight box.
Power measurements were made with a S170C sensor (Thorlabs).
4.2.3 TDI SFC Data Processing
Acquired spectral data was streamed from LabVIEW to a TDMS file. A custom, off-line
MATLAB code converted the TDMS data, reconstructed the spectral frames, and performed
subtraction of a smoothing spline background fit to 2000 consecutive frames not containing
signal. Frames without any event present were eliminated based on an S/N threshold of 20
(fluorescent beads) or 10 (cell samples). The resulting positive frames were analyzed to extract
event properties regarding time duration and fluorescence intensity. The detailed data processing
workflow can be found in SI Figure 4.1.
4.2.4 Microfluidic flow cell fabrication and fluidic connections
A brass mold master for the microfluidic flow cell was prepared using high precision-
micromilling (KERN 44, KERN Micro- und Feinwerktechnik) and carbide bits (Performance
Micro Tool). Devices were fabricated by hot embossing; upper platen temperature was 155 °C;
lower platen temperature was 80 °C; pressure used for embossing was 1250 psi with a 3 min
molding time, and demolding at 102 °C. A mold release agent (MoldWiz® F57-NC) was kindly
gifted from Axel Plastics and was coated on the molding tool. Embossed devices were diced with
a bandsaw, mechanically drilled to make ports, cleaned with 10% Micro-90®, IPA, and
nanopure water before thermal fusion bonding (105 °C, 2 h) with cleaned coverslips (250 µm)
76
made from the same material as the chip substrate. PEEK tubing was epoxy sealed to the
input/output ports. Microchannel dimensions were measured before and after thermal fusion
bonding using a laser-scanning, confocal profilometer (VK-X250, Keyence). The detailed
microfluidic flow cell fabrication and characterization information can be found in SI Figure 4.2.
The flow cell was mounted to the TDI SFC system via a 3-axis micrometer translational stage
(Thorlabs) and connected to two PicoPlus syringe pumps (Harvard Apparatus), one driving the
sample flow and another driving both sheath flows. Sample was introduced via a 2-position, 6-
port, manual injection valve (Idex Health and Scientific) with a PEEK, 20 µL injection loop.
4.2.5 TDI SFC System Optimization
For data without flow focusing, we infused InSpeck™ Green fluorescent calibration
beads (100% intensity) at 0.675 µL/min (average 2 mm/s) into a square glass capillary (75 µm
ID; Polymicro Technologies), that was mounted into the TDI SFC system and a section burned
to expose the imaged field-of-view. To synchronize flow velocity with TDI clocking, we infused
100% intensity calibration beads (~800 beads/µL) in 15% sucrose/PBS. We used dimmer (1%
intensity beads) for the collection of data to allow for the comparison of 10X and 20X
microscope objectives.
4.2.6 Pixel Calibration
To calibrate the pixels on the spectral direction to wavelength values, we used an optical
fiber to conduct the light source at different wavelengths with a 5 nm range at each wavelength
from a fluorometer and introduced the light into our TDI SFC. The data our TDI SFC recorded at
each wavelength were acquired and processed in MATLAB. The resulting data gave the pixel
number that showed the highest signal at each wavelength, allowing for pixel calibration.
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4.2.7 Simulations
Linear velocity profiles in the flow cell after merging of the sample and sheath flow
streams were simulated (COMSOL Multiphysics 5.2a) using geometry dimensions obtained
from laser scanning profilometry (SI Table 3). We simulated TDI readout with a custom time-
stepping simulation coded in Fortran 90 and compiled with GFortran (MinGW).
4.2.8 Statistical Analysis
Data sets were tested for normality via Shapiro-Wilk Normality Testing. We compared
non-normal data sets by Wilcoxon Rank Sum and Signed Rank Testing with R Studio v1.0.153
and R v3.5.1. Reported medians include all data. Box plot outliers were outside upper/lower
quartile ± interquartile range.
4.3 Results and Discussion
4.3.1 Optical Design of the TDI SFC System
The optical schematic and photograph of the TDI SFC is shown in Figure 4.1. For
excitation (shown in blue), we expanded a 488 nm laser (54 mW, spectrally filtered 488/6 nm)
and focused the beam to the back focal plane of a high numerical aperture, infinity-corrected
microscope objective (either 10X, 0.50 NA or 20 X, 0.75 NA) to establish widefield epi-
illumination. We tested two beam expanders to enlarge the laser excitation beam (21.2× or 7.1×).
In each case, we used a circular aperture to eliminate light outside the sensor’s visible field-of-
view (Köhler epi-illumination), which also improved excitation uniformity by cutting out the
edges of the laser’s Gaussian profile. With the 21.2× beam expander, we measured 4 mW (10.7
mW/cm2) excitation light through the microscope objective. Consolidating excitation with the
7.1× expander increased power to 21 mW (56.1 mW/cm2) but with less uniform flux (RSD in
power density increased from 2% to 15 %,).
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We collected fluorescence emission (shown in yellow in Figure 4.1A) through the same
microscope objective and split it from the excitation path via a dichroic mirror (495 LP). We
filtered emission (496 LP) before using an f-matched lens to focus the image onto a
spectrograph’s diffraction grating, which splayed the spectrally sorted emission along one axis of
a back-illuminated CCD. In our optical systems there was a removable mirror and two cameras,
one for TDI detection and one for system alignment. Because the TDI CCD did not provide full-
fame images when collecting spectral data from the illuminated specimen, it was difficult for
operators to know if the specimen was well aligned with respect to the imaging microscope
objective. Thus, we included a kinematically removable mirror to bypass the TDI SFC emission
optics and reconstruct the image on a standard CMOS camera via a tube lens. After alignment,
the mirror was removed to enable TDI SFC imaging.
Figure 4.1 (A) Schematic diagram of the TDI spectral flow cytometer. A beam expander and
epi-illumination lens produce widefield excitation in the flow cell from the filtered 488 nm laser.
Fluorescence emission is filtered and passed to a spectrograph grating that spectrally sorts and
focuses emission onto a back-illuminated CCD. A RGB CMOS camera was installed to serve as
an alignment camera. (B) A photograph of our in-house developed TDI spectral flow cytometer.
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4.3.2 Principle of TDI Synchronization
A schematic showing the operation of the TDI SFC is depicted in Figure 4.2A. The key
to detecting a fluorescently labeled cell using time-delayed integration resides in two CCD
operating aspects: 1) The cell’s image moves in the same direction as the CCD’s parallel shift
direction; and 2) the cell’s linear velocity should be synchronized with the CCD’s readout rate.
When these two conditions are met, the photoelectrical signal accumulates in only a few pixel
rows at readout, increasing the signal to noise ratio (SNR) in the resultant image [8]. If the
particles’ linear velocity and the CCD’s readout rate are not synchronized well, there will be
image “slur” [9], and the photoelectrical signal will be distributed in multiple pixel rows,
reducing the resultant SNR in the particle. With TDI, the CCD recorded a spectrum on each pixel
row.
To facilitate TDI operation, a CCD detector array with 100 pixel rows by 1340 pixel
columns was installed within the TDI SFC. The 100 pixels corresponded to the shift axis or time
axis while the 1340 pixels corresponded to the spectral axis. On the spectral axis, each pixel
corresponded to a wavelength value. The pixel calibration curve that converted pixel number to
wavelength is shown in Figure 4.2B. As illustrated in Figure 4.2B, our system was capable of a
spectral resolution of 0.7 nm/pixel with a fairly wide spectral range (500-1000 nm). The
rectangle shape of the CCD made sure that the spectral axis was wide enough to encompass
sufficient wavelength range. For the shift or time axis, 100 pixel rows corresponded to a 10-fold
increase in the SNR compared to a snapshot mode of CCD operation.
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Figure 4.2 (A) Schematic detecting a fluorophore-labeled cell in our TDI SFC. Because the
cell’s linear velocity and the CCD’s readout rate are synchronized, as the cell moving forward on
the shift or time axis, the fluorescent signal is transported and integrated within only a few pixel
rows at readout. Each pixel row on spectral direction collects a full spectrum due to the spectrum
dispersion by the spectrograph. (B) Pixel calibration on the spectral direction. Each pixel on
spectral direction corresponds to a specific wavelength value. Our system provides a high
spectral resolution of 0.7 nm/pixel and a wide spectral range (500-1000 nm) for data acquisition.
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If perfectly synchronized, the cell’s velocity will match the clocking of the fluorescence
spectrum, and the collected spectrum will be confined to a few readouts. For example, if the
image resolution of the system is 6 µm/pixel, a perfectly tracked 6 µm cell will register in only
one readout; with image size of 2 µm/pixel, three readouts. However, if a cell moves faster or
slower than the CCD’s time delay, the collected signal will “slur” over more readouts. We show
this effect theoretically in Figure 4.3. Mismatching between velocity and TDI shifting can cause
the CCD to readout fluorescence over longer time durations. Rather than a peak in signal, the
signal decreases and broadens, risking that the spectrum will not be detected above background
noise.
Figure 4.3 Theoretical TDI peak shapes for varying synchronization between cell velocity and
CCD delay time, where relative velocity of 1 indicates perfect synchronization.
To initially gauge the necessary velocity, we measured the readout time for the analog-to-
digital conversion of a single spectrum using our CCD, which was a minimum tdelay of 2 ms. The
measurement of the minimum delay time per pixel row is detailed in SI (SI table 4.1). Over the
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CCD’s 100 rows, the minimum integration time was then 200 ms. We measured the field-of-
view (FOV) of the TDI-CCD with a 10X objective (393 µm, 3.93 µm/pixel) by reference to the
focusing CMOS camera. The detailed measurements are given in SI (SI Figure 4.3 and SI table
4.2). Thus, for optimal TDI synchronization, the maximum linear velocity of a cell would be
393   /200  萨 = 2   /萨 at 10X magnification and 197   /200  萨 = 1   /萨 at 20X. For
slower velocities, we could increase the delay time for longer integration times and increased
signal. We also note that beyond this proof-of-concept demonstration, an alternative CCD with
faster readout could be implemented to increase maximum velocities at the cost of shortened
integration times.
4.3.3 Optimization of TDI Synchronization and Bead Signal-to-Noise Ratio (SNR)
We optimized the TDI SFC system using calibration beads (6 µm) with relative
fluorescence intensities from 0.3 to 100%. For a frame of reference, we compared these beads,
which have an arbitrary intensity ranging from 0.3% to 100%, to antibody binding capacity
(ABC) beads to find out the antibody loads for each bead population. ABC beads contain Fc-
specific receptors and carry a known, quantitative load of fluorescent antibodies. Both calibration
beads and ABC beads were measured by traditional flow cytometry on the same run (Figure 4.4).
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Figure 4.4 Labeled anti-mouse IgG Fc-specific beads with varying antibody binding capacity
with mouse, anti-human TdT-FITC antibodies. Each population of ABC beads was measured
using a traditional flow cytometer and the mean fluorescence intensity (MFI) was extracted.
Fluorescence from the fluorescence calibration beads was then measured, and the calibration
beads MFI values were correlated with the ABC values. The linear fit between MFI and ABC
values is shown in black (R2 = 0.995). A linear fit was also obtained between MFI and percent
fluorescence for the calibration beads (data not shown, N=2, R2 = 0.996). Note that we subtracted
all positive populations with the MFI of their respective blank, unlabeled beads.
Only the 0.3% calibration beads were within the dynamic range of the ABC beads (3.8
±0.2×105 antibodies). However, assuming linearity beyond the ABC populations available, the
1% calibration beads would correspond to a load of 2.2 ±0.1×106 antibodies. For a frame of
reference, direct immunolabeled surface antigens typically fall in a range of 104-105 antibodies
per biological cell. Therefore, the 0.3% to 100% fluorescence intensity corresponded to loads of
3.8 ±0.2×105 to 1.3 ±0.1×108 fluorescent antibodies, respectively (Figure 4.4). Because directly
immunolabeled surface antigens typically fall in a range of 104-105 antibodies per biological cell,
we aimed to achieve high sensitivity for the dimmest beads (0.3% intensity). Thus, we will
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describe sequential improvements to the TDI SFC system’s synchronization and fluorescence
sensitivity (Table 4.1) before applying the optimized system to the immunophenotyping of a B-
ALL cell line against the TdT leukemic antigen.
We note that a cell or bead will generate a TDI signal S(λ,t), which is a fluorescence
spectrum dispersed by wavelength (λ) and read over time duration (Δt). With improved
synchronization between cell velocity and TDI clocking, peak signal will be maximized, and
event duration will be minimized (see peak shapes in Figure 4.3). Thus, for variables that affect
TDI synchronization (Table 4.1), we monitored Δt and the peak signal Speak observed over Δt at
the maximum emission wavelength λmax:
      = max       h     (Eq. 4.1)
For variables that only affect the system’s fluorescence sensitivity, such as excitation
power, we accumulated all integrated signal Sint throughout the event’s duration and across all
wavelengths:
     = 0
                 (Eq. 4.2)
We also calculated the SNR for each event by dividing the accumulated signal by noise
in the readout. To account for both dark noise, read noise, and shot noise, we fit the integrated
spectrum with a smoothing spline function Ffit(λ) (Figure 4.5) and calculated noise from the
square root of the residual’s sum of squared errors (SSE):
A TDI event consists of a fluorescence spectrum read over time, S(λ,t). To assess the
effect of the variables in Table 4.1 on fluorescence sensitivity, we accumulated all signal
collected by the CCD by integrating the total signal Sint over all wavelengths and over the event’s
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duration Δt. We then evaluated noise in each fluorescence spectrum integrated over time,
i.e., 0
             , by fitting a spline function Ffit(λ).
Figure 4.5 An integrated spectrum was fit with a spline function (smoothing parameter = 0.1).
Residuals in the fit represented noise in the integrated signal, quantified by the sum of square
errors (SSE).
The residuals from the fitting function represent noise in the integrated spectrum that was
quantitated by the sum of square errors (SSE) over all wavelengths. We note that we did not
observe a dependence on the signal-to-noise ratio on the wavelength region used to sum the
noise. An example of the fitting process is shown in Figure 4.5, where an increase in shot noise
is evident as the fluorescence signal increases.
Table 4.1 Variables tested for the TDI SFC system that improved TDI synchronization and/or
fluorescence sensitivity. The related data are summarized by median improvement to Speak or
SNR.
TDI SFC variable Range Improvement Figure
Cell focusing None 1D focusing Synchronization: 4.5× Speak, 0.8× Δt 4.6
Cell velocity 1.41 1.83 2.11 mm/s Synchronization: 2.3× Speak, 0.5× Δt 4.7
Excitation power 4 21 mW Sensitivity: >9× Sint 4.8
Objective NA 0.5 0.75 NA Sensitivity: 2× Sint, 1× SNR 4.9, 4.10
TDI integration time 200 400 ms Sensitivity: 8-10× Sint, 4× SNR 4.11
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4.3.3.1 One Dimensional Microfluidic Focusing for Improved TDI Synchronization
Hydrodynamic flow generates non-uniform velocities throughout a capillary or
microchannel’s cross-section, which can cause variable TDI synchronization from cell-to-cell.
We observed this effect by infusing fluorescent beads through a 75 µm square, glass capillary at
an average velocity of 2 mm/s with a 200 ms integration time. Note that in all cases, we verified
the TDI SFC focal plane was focused to the center of the capillary or microchannel using the
focusing system and a micrometer sample mount. We counted TDI signals when the collected
spectrum increased 20× above background noise and analyzed events for time duration Δt and
Speak at the bead’s emission maximum (515 nm). In unfocused hydrodynamic flow, TDI signals
ranged from 24-124 ms in duration, and many events lacked a peak signal characteristic of
synchronized TDI and instead exhibited flat, constant signal (Figure 4.6B).
To improve velocity uniformity, we employed a microfluidic flow cell with a T-junction
that merged sheathing buffer on either side of the sample stream to provide 1D focusing along
the lateral, x-direction of the flow cell (Figure 4.6A). This compressed the sample stream into a
more uniform lateral position, thereby improving velocity uniformity through the microchannel’s
cross-section (SI Figure 4.4A). Without optimizing cell velocity to CCD clocking (average
velocity 1.6 mm/s, maximum 2.4 mm/s), we observed more uniform event durations, most
frequently at 64 ms (Figure 4.6C) with peak shapes characteristic of TDI synchronization.
Indeed, Speak increased by 4.6× with microfluidic 1D focusing (Figure 4.6D). Also, the event
lengths distribution of 1D focusing showed higher uniformity than no-focusing (Figure 4.6C).
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Figure 4.6 (A) A bright field image of the T-shaped microfluidic flow cell and a fluorescent
image showing hydrodynamic focusing in the flow cell using 50 mM FITC solution and
deionized water. (B) TDI imaging of fluorescent beads (100%) without focusing (red) or with
1D microfluidic focusing (blue). Shown are spectra acquired over 2 s with background data
between events removed. We plotted a bead spectrum along the CCD’s wavelength axis and the
signal at λmax (515 nm) over time. Box plots of (C) event duration and (D) Speak. In box plots:
middle line shows median; edges of box, upper and lower quartiles; bars, minima and maxima
excluding outliers; squares, averages; and dots, all data. Statistical analyses showed p<10-2 (**)
and p<10-4 (****).Sample and sheath flow rates were 0.178 and 0.217 uL/min, respectively, and
10X objective with 4 mW excitation was used for both data sets.
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We then optimized flow conditions for 1D microfluidic focusing by maintaining the
sample flow rate and increasing the sheathing rate. Thereby, we increased maximum velocity in
the sheathed sample stream from 1.41 to 2.11 mm/s while decreasing the width of the sheathed
sample stream from 24 µm to 16.4 µm (SI Figure 4.4B). Examples of a well-synchronized and a
bad-synchronized bead event are shown in Figure 4.7A. We maintained a constant integration
time of 200 ms and observed an optimal velocity (1.83 mm/s) that maximized peak signal
(median, 13,430 counts) and minimized event duration (median, 36 ms) with statistical
confidence that the observed differences were not due to sampling error (p<10-4, Figure 4.7B).
These trends agree within 10% of theoretical calculations and illustrate that as TDI
synchronization is optimized, signals are read as narrower, more intense peaks (Figure 4.3).
Lastly, we note that the TDI SFC optical system does not use a confocal pinhole to block
out-of-focus fluorescence. Cells not focused along the microchannel’s 93 µm depth can be
detected but will have lower signal, variable velocity, and imperfect synchronization (SI Figure
4.5). In future renditions of the TDI SFC system, we will employ 2D focusing to improve upon
the gains made by 1D microfluidic focusing herein.
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Figure 4.7 (A) Examples of a well-synchronized and a bad-synchronized events. The well-
synchronized event showed relatively short time duration and bright fluorescence while the bad-
synchronized event was a “slur” and showed dim fluorescence. (B) Flow optimization of TDI
synchronization in the 1D microfluidic flow cell, showing box plots of event duration (red) and
peak signal at 515 nm (blue) at varying maximum velocities. Data acquired with 10X objective
and 4 mW excitation. Statistical analyses showed p<10-4 (****).
4.3.3.2 Optimization of TDI SFC Sensitivity for Weak Fluorescence Signals
All experiments to optimize TDI flow synchronization used beads with 100% relative
fluorescence intensity. These beads correspond to a load of 108 fluorescent antibodies, 1,000-
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10,000× greater than expected for biological cells. Therefore, we evaluated other methods to
increase the TDI SFC’s sensitivity.
4.3.3.2.1 Optimization of Excitation Power
We first increased the excitation power in the objective’s field-of-view from 4 to 21 mW
(Figure 4.8A). We enlarged a 488 nm excitation laser (54 mW) with a beam expander then used
a circular aperture to cut the edges of the Gaussian laser beam. The circular aperture was closed
(diameter d = 4.7 mm) to eliminate illumination outside the CCD’s sensors field-of-view,
thereby establishing Köhler epi-illumination. This also served to reduce non-uniformity in
excitation power density through the field-of-view by eliminating light on the edge of the
Gaussian beam’s profile.
After beam expansion, the beam’s radius (w = 1/e2 = 0.65 mm) was enlarged by a factor
of 7.1× and 21.2× to w = 4.6 mm or 13.8 mm, respectively. With both beam expanders, the total
beam power P0 = 54 mW remained constant, but as the beam expanded, the laser power density
became more uniform while decreasing in magnitude (Figure 4.8A). The profile of the enlarged
beams is given by a Gaussian function over radius r:





Integration of Eq. 4.4 over the aperture’s fixed surface area, πd2/4, shows that the total
power should increase from 5.7 mW to 40.6 mW when decreasing the beam size with 21.2× and
7.1× beam expanders. These theoretical calculations agree well with the experimental
measurements of 4 mW and 21 mW, respectively. Lastly, we note that while the power density
non-uniformity increases to 15% (RSD) with the 7.1× beam expander, even the lowest intensity
excitation at the edge of the field-of-view surpasses the power density achieved with 21.2× beam
expander (Figure 4.8A).
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The signal at λmax from the 100% intensity beads increased beyond the CCD’s dynamic
range (Figure 4.8B). Thus, we evaluated Sint at 550 nm, where the CCD was not saturated, and
observed a 9.8× increase in Sint (5.2×106 to 4.7×107 counts for 4 to 21 mW, respectively).
Figure 4.8 (A) Theoretical power density of the 488 nm excitation laser through the epi-
illumination aperture for the 7.1× and 21.2× beam expanders. (B) Signals for 100% intensity
beads at 4-21 mW excitation.
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4.3.3.2.2 Higher NA objective
Given the enhanced signal with increased excitation power, we evaluated dimmer beads
with relative intensities of 0.3% to 10% (corresponding to 3.8×105 to 5.0×106 Abs, Figure 4.4)
with the 10X objective (0.50 NA). We observed a linear increase (R2 = 0.99) in median Sint from
1.0×105 to 8.3×106 counts from 0.3% to 10% intensity (Figure 4.9A) and a 152 SNR (median)
for the dimmest, 0.3% intensity beads (Figure 4.9B).
Figure 4.9 (A) Sint and (B) SNR for 0.3%-10% beads at 10X (0.50 NA) or 20X (0.75 NA), 21
mW.
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We repeated these experiments with a 20X objective with a higher NA (0.75) to increase
the amount of emission gathered. We observed a substantial increase in signal and could not
analyze the 10% intensity beads due to CCD saturation. For 0.3% to 3% intensity beads, the
median Speak increased by 7.5-10.2× (Figure 4.9A) and SNR values increased by 4.0-4.8×
(Figure 4.9B), respectively. The dimmest 0.3% beads produced a median Sint of 1.1×106 counts
(Figure 4.9A) at a SNR of 610 × (Figure 4.9B), and median Sint again increased linearly with
bead intensity (R2=0.99) to a median SNR of 1,820 for 3% intensity beads.
As an example, the substantial signal increase on 1% relative intensity beads is shown in
Figure 4.10. As a note, we included only data that surpassed a threshold of 20× the signal-to-
background noise. We also removed all background data between events, so we could show
several events on the same plot.
Figure 4.10 TDI signals at 515 nm for the 1% intensity calibration beads, integrated for 200 ms
using a 10X objective (NA=0.50, 1.83 mm/s) or a 20X objective (NA=0.75, 0.92 mm/s).
Statistical analysis is provided in Figure 4.9.
4.3.2.2.3 Higher full-frame integration time
The above data represent substantial gains in sensitivity for fluorescent calibration beads
that approach the expected load of Abs on immunolabeled cells, but these gains come at a cost of
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reduced sample processing rate (i.e., throughput). For example, increasing the NA of the
collection optic reduced the field-of-view by a factor of 2. Given a constant integration time (200
ms), we had to reduce all flow rates by ½ to maintain an optimized velocity of 0.92 mm/s for
TDI synchronization (Figure 4.10).
In a similar manner, we halved the sample velocity when doubling the integration time
from 200 ms to 400 ms (Figure 4.11). The 1.97× increase in Sint resulted in only a minimal
change in SNR (p = 0.071). Thus, when analyzing cells, we chose to use the 20X objective (0.75
NA), 200 ms integration time, and 21 mW excitation power.
Figure 4.11 (A) TDI signals at 515 nm for the fluorescent calibration beads integrated for 200
ms (2.0 mm/s) or 400 ms (0.92 mm/s) using 100% intensity calibration beads and a 10X
objective. (B) Box plots for increased integration time, 3% beads at 10X. Unless noted, statistical
analysis showed p<10-6.
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4.3.4 TDI SFC Detection Efficiency and Throughput
To evaluate detection efficiency, we processed concentrations of fluorescent beads (3%
intensity, 10X objective, 200 ms integration) from 200-1,500 beads/µL and measured the bead
concentration by dividing the number of beads detected by the sample volume processed. We
note that there is no limit for lower bead concentrations; we designed these experiments to test
the upper limit of throughput. We correlated results to a commercial MFC (BD Accuri C6 Plus).
From 200 to 750 beads/µL, we observed high concordance (R2 = 0.97) between the systems in
terms of the number of beads detected (Figure 4.12 left).
At concentrations above 750 beads/µL, TDI SFC detection efficiency decreased, and the
number of detected events remained fairly constant. Upon inspection of TDI signals, a
substantial number of events contained multiple, unresolved beads overlapping in time (starred
in Figure 4.12 right).
Figure 4.12 TDI SFC measurements of bead concentration (3% intensity, 10X objective, 200 ms
integration) compared to a commercial MFC instrument. (left) TDI SFC detection efficiency
compared to commercial MFC. (right) At high bead concentration, coincident beads were not
resolved (noted as red stars).
To calculate the probability of occupancy in the TDI SFC field-of-view, we calculated
the detection volume (673 pL) using the sheathed sample width (18.6 µm, SI Figure 4.4B) and
assumed that beads can be detected throughout the microchannel’s depth (92 µm) and the CCD’s
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field-of-view (393 µm). We calculated the probability that k beads would occupy the field-of-
view simultaneously (Figure 4.13) by a Poisson distribution (P(k)=e^(-λ) λ^k/k!, where λ is the
average occupancy (bead concentration multiplied by the detection volume). The probability of
coincident events based on Poisson statistics (Figure 4.13) were calculated to be 1%, 10%, and
27% for 200, 750, and 1,500 beads/µL, respectively. This indicates a upper throughput of 90
beads/min (750 beads/µL) in the current TDI SFC system.
Figure 4.13 Poisson distributions showing multiple bead occupancy over bead concentrations
relevant to Figure 4.12.
TDI operation should be capable of resolving coincident events, but the current 1D
microfluidic focusing strategy does not focus events along the z-direction. Beads with varying
velocities and slurring from imperfect synchronization can lead to event overlap. Variability in
the z-axis travel of beads also affects the consistency in an event’s fluorescence intensity. This
can increase the coefficient of variation (CV) for a single bead population.
We measured 3% intensity beads with a commercial MFC and by TDI SFC and measured
signal as the mean fluorescence intensity (MFI) or Sint, respectively (Figure 4.14). Commercial
MFC yielded a narrow distribution centered at 5.4×105 counts with a 5.7% coefficient of
variation (CV = MFI/standard deviation). Integrated TDI signals were non-Gaussian, skewed
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because slower beads are imaged by the CCD longer and generate increased Sint even though
Speak decreases. While the non-Gaussian distribution makes the traditional CV inappropriate, we
report an average Sint of 2.2×106 counts with a traditional CV of 69.1%. More appropriately, we
calculated the CV based on the median signal divided by the interquartile range (refer to box plot
inlaid in Figure 4.14). This yielded a median Sint of 1.9×106 and a reduced CV of 24.2%. The
relatively high variation in signal by TDI SFC can be attributed to variability in bead position in
the z-axis focal plane using 1D microfluidic focusing.
Figure 4.14 Histograms of fluorescence intensity for 3% intensity beads measured with a
commercial MFC and TDI-SFC (10X objective, 200 ms integration). For the TDI-SFC data, a
box plot is inlaid to show skew in the signal distribution that led to using the interquartile
distance divided by median value for calculating the CV.
4.4 Conclusion​
A unique TDFI-SFC instrument was reported for the automated immunophenotyping of
rare, low abundant biological cells. CCD readout of high-resolution fluorescence spectra was
conducted in a TDI mode, ensuring that rare cells would not be missed because the sensor duty
cycle approached 100% and the fluorescence intensity was high even for weak emitting events.
The TDI SFC could correctly identify rare cells due to the ability to acquire the entire
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immunolabels’ fluorescence emission spectrum to allow for spectral deconvolution as opposed to
conventional MFC, which typically requires >20,000 events to set gating thresholds for cluster
analysis. This attribute will be particularly important for enumerating CLCs for monitoring MRD
because the biological specificity of the affinity agent is modest and the number of cells enriched
makes it operationally difficult to use fluorescence microscopy.
In this chapter, the TDI SFC was characterized using a biological cell model, fluorescent
beads. A microfluidic flow cell with T-geometry of channels was fabricated and used as a
hydrodynamic flow focusing device. To validate the benefit of 1D hydrodynamic focusing in the
microfluidic flow cell, data comparison to non-flow focusing was undertaken. As expected,
using 1D hydrodynamic focusing produced higher fluorescence signal and tighter event length
distribution. We also used the fluorescent beads and tried multiple flow rates in the T-shaped
microfluidic chip to find out the optimal flow rate for TDI synchronization. And it suggested that
a linear velocity of 1.83 mm/s of the beads provided the best synchronization. To further
improve the sensitivity, optimizations such as using higher power excitation source, using a
higher NA objective and adding a delay time to the TDI CCD were performed. These
optimizations successfully increased the fluorescent signal by 9× Sint, 2× Sint with 1× SNR and 8-
10× Sint with 4× SNR, respectively. The dynamic range of throughput was also explored by
testing the same bead population with various concentrations in our TDI SFC and a commercial
MFC. The results indicated a upper throughput of 90 beads/min (750 beads/µL) in the current
TDI SFC system. All of these characterizations were necessary and critical to facilitate






1 MATLAB data processing workflow
2 Fabrication, thermal fusion bonding and channel dimension
characterization of the microfluidic flow cell
3 Measurement of minimum delay time per pixel row
4 Measurement of FOV
5 COMSOL fluid dynamic simulations for the microfluidic flow cell
6 Fluorescence signals for out-of-focus particles/cells
1. MATLAB data processing workflow
SI Figure 4.1MATLAB data processing steps and the detailed processes in each step.
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2. Fabrication, thermal fusion bonding and channel dimension characterization of the
microfluidic flow cell.
SI Figure 4.2 Fabrication and channel characterization of the microfluidic flow cell. (A) Produce
the brass mold by high-precision micromilling. (B) Transfer the mold structure to the PMMA
polymer substrate by hot embossing. (C) Use thermal fusion bonding to plug the microfluidic
flow cell. (D) Use a laser-scanning confocal profilometer to characterize the microfluidic
channel dimensions before and after thermal fusion bonding to ensure proper structure fidelity.
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3. Measurement of the minimum delay time of our TDI SFC.
The delay time per pixel row can be expressed as:
tdelay = Nx tst + tv + ti + td (Eq SI 4.1)
Thus, the full frame integration time tint of TDI can be expressed as:
tint = tdelay ∗ Ny = [Nx tst + tv + ti + td]Ny (Eq SI 4.2)
Where Nx is the number of pixels at spectral axis (Nx =1340 in this study), tst is the time it takes
to shift one pixel out of the serial register, tv is the time it takes to digitize one pixel, ti is the time
it takes to shift the photoelectrical signals from one pixel row to the next pixel row, td is the
secondary delay time that can be manually set on the Labview software user interface of our TDI
SFC, and Ny is the number of pixels on shift direction (Ny=100 in this study).
The minimum tdelay is when td is set as 0. Despite of the expression of the minimum delay
time per pixel row, it is unnecessary to measure tst, tv or ti respectively to know tdelay. Instead, tdelay
can be calculated by collecting TDI data. Specifically, if the data acquisition time is recorded and
the number of frames is obtained from data processing in MATLAB, the minimum tdelay per pixel




  td (Eq SI 4.3)
Where ta is the TDI data acquisition time, Na is the number of frames acquired and it can be
obtained after processing the data in MATLAB, and td is the secondary delay time that can be
manually set on the Labview software user interface of our TDI SFC. The measurements of the
minimum tdelay per pixel row are shown in SI Table 4.1.
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SI Table 4.1Measurements of the minimum tdelay per pixel row.
From our measurements, the minimum tdelay per pixel row was 0.002s. Thus, the
minimum full frame integration time tint for the 100 pixel rows was 0.2 s.
4. Measurement of FOV with a 10x objective
The FOV was measured by mounting a glass slide containing fluorescent calibration
beads sealed with a glass coverslip. It was measured with reference of the CMOS alignment
camera. An example measurement is shown in SI Figure 4.3. By recording the full frame
snapshots from the CMOS alignment camera and our CCD camera of one bead at two different
vertical positions (Y axis in SI Figure 4.3), the FOV could be measured.
103
(A) (B)
SI Figure 4.3 (A) When the bead was in position 1 it corresponded to a position of Y=1019
pixels on the focusing camera and a position of Y=37 pixels on the full frame image of TDI CCD.
(B) After changing the bead’s position to position 2, it corresponded to a position of Y=633
pixels on the focusing camera and a position of Y=77 pixels on the full frame image of TDI CCD.
The bead’s position difference on the focusing camera was 1019-663=356 (pixels).
Through a calibration slide on the focusing camera we could get the pixel calibration information
of 0.4338 µm/pixel. Thus, the physical position difference between position 1 and position 2
could be calculated as:
356 pixels×0.4338 µm/pixel =154.4 µm.
The TDI CCD had 100 pixels on Y axis (time axis or shift direction). Since the bead’s physical
position difference resulted in a difference of 77-37=40 (pixels) on the full frame images on TDI,
the FOV on the time axis could be calculated as:
FOV = 154.4 µm
40 pixels
×100 pixels = 390 µm
Three trials of the measurements are shown in SI Table 4.2:
SI Table 4.2Measurements of FOV
Trial 1 Trial 2 Trial 3 AVG
390 µm 389 µm 401 µm 393.3µm
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5. COMSOL fluid dynamic simulations for the microfluidic flow cell
We evaluated the flow velocity profiles within the microfluidic T-cell with hydrodynamic
focusing using 3-D laminar flow simulations in COMSOL Multiphysics 5.2a. We constructed the
geometry using measurements of the microchannel cross section obtained from laser scanning
profilometry, which we provide along with all other parameters of the simulations in SI Table
4.3. We evaluated the flow profile in the square bore capillary with no hydrodynamic focusing
using the same simulation parameters, except that the geometry was designed as a 1 mm long
segment of a 75 µm square channel. We show axial cross sections of the velocity flow profiles in
the sheathed sample stream in SI Figure 4.4A with the maximum velocities and core widths
noted. Results for the square capillary are not shown, but these results indicated a maximum
velocity of 4.19 mm/s and average velocity of 2 mm/s for the volume flow rate tested, which was
0.675 µL/min. We also note that we observed variation in the maximum wavelength of bead
spectra during TDI SFC imaging, which correlates with the core width of the sheathed sample
stream (SI Figure 4.4C), because the spatial x-axis is spectrally sorted into the wavelength axis
of the TDI SFC CCD (see Figure 4.2).
SI Table 4.3 All simulation parameters for 3-D COMSOL Multiphysics simulations of velocity
fields.
Simulation parameter Value
Geometry lengths 1.5 mm (sample), 1 mm (both sheaths)
Geometry height 92.6 µm
Geometry width (top) 124.6 µm
Geometry width (bottom) 70.6 µm
Fluid properties Water
Wall conditions No slip
Inlet condition 0.12 µL/min (sample), 0.12-0.21 µL/min
(sheath)
Outlet condition 0 Pa
Initial values 0 velocity field, 0 pressure drop
Meshing preset Physics-controlled, “Extra fine”
Number of elements 2,823,023
Element size 0.456-7 µm
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Maximum element growth rate 1.08
Resolution of curvature 0.3
Resolution of narrow regions 0.95
Number of boundary layers 2
Boundary layer stretching factor 1.2
Thickness adjustment factor 5
Solution type Stationary
Solver GMRES, fully coupled (default settings)
Relative tolerance for convergence 10-3
SI Figure 4.4 (A) 3-D COMSOL simulation results for the microfluidic T-shaped flow cell with
hydrodynamic flow focusing showing streamline plots viewed from the top (top-left panel), side
(bottom-left panel), and cross-section (right panel) for a sheath flow rate of 0.210 µL/min. (B)
Table showing the maximum velocity and core width of the sheathed sample stream for the
sheathing rates tested in the main text. No sheathing fluid indicates values for the sample channel
alone. (C) Variation in the peak wavelength for bead spectra (obtained with a sheath rate of
0.174 µL/min) correlates with variation in bead position along the x-direction of the flow cell
(core width).
6. Fluorescence signals for out-of-focus particles/cells
The effective Z-axis spread of particle travel in our system was set by the microfluidic T-
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cell depth of 92 µm. To test the amount of fluorescence processed by the TDI SFC system when
in/out of focus, we dispensed fluorescent calibration beads diluted in water onto a glass slide,
sealed the slide with a coverslip, and placed the slide within the TDI SFC system and imaged
through the coverslip. We focused on a single bead via the focus system’s CMOS camera
(Figure 4.1A). We displaced the bead out of the focal plane as measured by a micrometer X-Y-Z
sample stage and recorded images of the out-of-focus fluorescence (SI Figure 4.5). Changes in
the bead’s image were apparent after a 30-µm displacement from the focal plane. After a 50-µm
displacement, which is beyond the maximum deviation allowed by the 92 µm deep microfluidic
focusing channel, the image was further distorted with signal being dispersed onto a larger area
of the CCD. These data illustrate that while 1D focusing does not constrain particle position in
the Z-direction, particles may still be detected by the TDI SFC system, albeit with higher
variation in signal intensity. In addition, variation in the flow velocity along the z-axis (see SI
Figure 4.4A) will also cause some particles/cells to not be synchronized to the CCD clocking
rate.
SI Figure 4.5 (A) Images from the CMOS focus camera of a single fluorescent bead translated
out of the TDI-SFC system’s focal plane using a micrometer positioning stage. (B) Line
fluorescence profiles across the bead showing that the bead when shifted out of the system’s
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CHAPTER V
Application of Spectral Flow Cytometry with Time-Delayed
Integration (TDI SFC)
5.1 Introduction
As a demonstration of the TDI SFC system, we undertook the immunophenotyping of
CLCs from patients with B-cell acute lymphoblastic leukemia (ALL). In acute leukemias,
patients in remission may harbor drug resistance, and residual disease that can progress from low
measurable residual disease (MRD) to lethal levels in weeks to months.1,2 Due to this rapid
progression, frequent MRD surveillance is paramount to tailor patient-specific treatment
strategies.2,3 MFC analysis is commonly implemented to monitor B-ALL MRD using bone
marrow aspirates4, where leukemic cells are differentiated by abnormal expression of
hematopoietic proteins.5 MFC can detect marrow-derived leukemic cells at a frequency of 10-3 –
10-4, but this sensitivity does not extend to peripheral blood due to hemodilution of CLCs.6 Thus,
standard-of-care MRD monitoring is limited by invasive bone marrow biopsies due to the high
occurrence of leukemia cells in the bone marrow, and as such, monitoring for MRD can occur
every few months. However, rapid relapse events associated with acute leukemias require
weekly samplings to begin therapeutic intervention early to potentially provide better patient
outcome.2
We recently demonstrated a microfluidic assay3 to affinity-enrich CLCs from the
peripheral blood of patients with acute myeloid leukemia (AML). The surfaces of microfluidic
devices were coated with antibodies that selected myeloid cells from blood, and CLCs were
identified by immunostaining against patient-specific leukemic antigens.3 Depending on the
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patient’s disease state, total cell counts (10-100,000 cells/sample) and CLC frequencies (0-98%)
were detected.3 We have observed similar trends in an ongoing project for B-ALL patients in
which CLC enrichment from blood was enabled by using microfluidic devices coated with anti-
CD19 antibodies; CLCs were differentiated from normal CD19(+) cells by immunostaining
against the nuclear protein TdT (terminal deoxynucleotidyl transferase).7 Given the sample-
limited cell counts, we released cells from the microfluidic device8 for immunophenotyping by
semi-automated fluorescence microscopy. While reliable, this process required lengthy manual
cell counting.3 Unfortunately, in many cases the CLC levels were below what could be
accurately processed using MFC.
Therefore, we developed a spectral flow cytometer with time delayed integration mode
(TDI SFC). The TDI SFC system was characterized using cell models, fluorescent calibration
beads, in the previous chapter. In this chapter, we applied the system to the proof-of-concept
immunophenotyping of a B-ALL cell line labeled against several markers and positively
identified these cells. These data support the great potential of the TDI SFC for automated
immunophenotyping of rare cells in diverse applications, including the longitudinal surveillance
of residual disease in leukemias3 and epithelial cancers.9
We also developed and optimized unmixing algorithms for spectral deconvolution for our
TDI SFC. Spectral deconvolution ablates the need for extra samples and experiments for spectra
compensation, giving rise to our TDI SFC’s great potential for sample-limited CLC
immunophenotyping and disease monitoring.
5.2 Experimental Methods
5.2.1 Reagents and Materials
The materials for microfluidic chip fabrications were the same as the previous chapter.
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Reagents included: methanol-stabilized formaldehyde (37%), methanol-free formaldehyde
(16%), phosphate buffered saline (1X PBS, pH=7.4) LIVE/DEAD™ Cell Imaging Kit
(488/570), 7-aminoactinomycin D (7-AAD), and InSpeck™ Green fluorescent calibration kit
from Thermo Fisher Scientific; FITC-labeled, mouse anti-human terminal deoxynucleotidyl
transferase (anti-TdT) antibody from BioRad (cocktail of clones HT-1, HT-4, HT-8, HT-9);
sucrose from Fluka; Histopaque®-1119, Triton™ X-100, Micro-90®, reagent-grade isopropanol
(IPA) from Sigma-Aldrich; and anti-mouse Fc-specific Antibody Binding Capacity (ABC) beads
from Bangs Lab. The cell filters for removing cell clumps and hemocytometer for cell counting
were purchased from Thermo Fisher Scientific.
5.2.2 TDI SFC Data Processing
Acquired spectral data was collected and processed in MATLAB as described in previous
chapter. Frames without any event present were eliminated based on a signal-to-noise threshold
of 20 (fluorescent beads) or 10 (cell samples). The positive events were analyzed to extract event
properties regarding time duration and fluorescence intensity. The frames in each positive event
were integrated to obtain the total emission spectrum of. For multiplexed staining, total emission
spectra were deconvoluted using classic least squares unmixing10 from spectra acquired from
singly-stained cells and autofluorescence in unstained cells.
5.2.3 Microfluidic Flow Cell Fabrication and Fluidic Connections
The 1D focusing microfluidic devices were fabricated using the same processes as
described in the previous chapter. The fabrication, thermal fusion bonding and channel
dimension characterization were the same as the previous chapter and were detailed in the SI of
the previous chapter.
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5.2.4 Cell Culturing, Immunostaining and Analysis
SUP-B15 ALL cells (ATCC CRL-1929) were cultured at 37 °C, 5% CO2 in Iscove’s
Modified Dulbecco’s Medium with 20% fetal bovine serum (Gibco Laboratories) and 0.02 μL 2-
mercaptoethanol (MP biomedicals) per mL media. Cells were washed with PBS (300×g, 7 min)
twice before and after staining processes, followed by resuspension in Histopaque®-1199. For
nuclear staining, cells were fixed with 2% formaldehyde (15 min), permeabilized with 0.1%
Triton™ X-100 (10 min), and stained with anti-TdT-FITC (10 µL/106 cells) and/or 7-AAD (4
µM) for 40 min. Unstained cells were fixed with 2% formaldehyde. For calcein staining (0.5 µM,
15 min), cells were fixed with 2% methanol-free formaldehyde to maintain membrane integrity.
Successful staining was confirmed by plating cells on a glass slide and imaging with a Zeiss
Axiovert 200M fluorescence microscope, XBO 75 Xe arc lamp, single band FITC (Ex: 470/20,
Em: 535/40) or Cy3 (Ex: 540/25, Em: 605/55) filter set (Omega Optical), Cascade:1K EM-CCD
camera (Photometrics), and MAC 5000 stage (Ludl Electronics Products). The cells were filtered
with a 30 µm filter and the cell concentration was determined using a hemocytometer before
introducing them to the TDI SFC with a 20x objective.
5.3 Results and Discussion
5.3.1 Detection of Leukemic Cells with Calcein Stain
The first cell sample tested by the TDI SFC were SUP-B15 ALL cells stained with
calcein. Calcein acetoxymethyl (calcein AM) is a frequently used cell viability reagent that is
nonfluorescent. However, calcein AM can be transported through live cell surface membrane to
the intracellular matrix and generate fluorescent calcein molecules with the presence of esterases.
The detachment of acetoxymethyl (AM) groups under the catalysis of esterase makes the calcein
molecules fluorescent, which shows the highest emission at 516 nm with optimal excitation
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efficiency at 495 nm, allowing for the cell viability information. Calcein stain in live cells is
known for its bright green fluorescence signal. Since our TDI SFC adopts a 488 nm laser light
source which can excite calcein molecules with high efficiency, calcein-stained leukemic cells
were chosen to be tested by the system as an initial validation of application. A critical fact about
calcein stain is that the cell membrane must be intact to keep the fluorescent calcein molecules
inside. If the cell membrane is compromised, the calcein molecules will not be confined in the
cytoplasms and will lead to failed staining process. Figure 5.1 shows the microscopy data and
TDI SFC data from this cell population.
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Figure 5.1 Detection of the calcein stained leukemic cells. (A) Left: a bright field image of the
cells. Right: the same cells imaged in FITC channel to show the calcein signal. (B) Plot at the
maximum emission (516 nm) cross the calcein-stained cell events detected by our TDI SFC. (C)
A spectrum recorded by one frame from a cell event (green) showed agreement with the
reference emission spectrum of calcein (orange).
The bright field image of some calcein AM treated cells and the same cell image in
fluorescent channel are shown in Figure 5.1A. The bright field image displays all of the cells in
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the field of view while the fluorescent image only shows the cells with successful staining. From
the images it can be concluded that not all of the cells were successfully stained with calcein.
This is mainly because of two facts. First, some of those cells were dead cells and had
compromised cell surface by the time of staining. One reason attributing to this is apoptosis.
Apoptosis is a genetically controlled process that results in programmed cell death to remove
cells, mainly aged or unhealthy cells, to maintain appropriate cell numbers. 11 When a cell is
apoptotic, although the cell can be clearly observed in the bright field image, the surface
membrane integrity cannot be guaranteed, resulting in failed calcein staining. Second, although
the healthy live cells were stained well when being treated with calcein AM, in the later sample
preparation processes of spinning down, vortexing and pipetting to remove excess calcein AM
molecules, the cell surface of some cells were ruptured due to mechanical agitation, causing
release of celcein molecules from the cytoplasms.
Despite the fact that not all of the cells in the bright field image were stained with calcein,
the successfully stained cells were able to be detected by the TDI SFC. The plot at the maximum
emission (around 516 nm) across some representative positive events after background
subtraction is shown in Figure 5.2B. The peaks in this figure indicates the positive calcein cell
events. To validate the reliability of the data obtained from the TDI SFC, we also compared the
experimental spectrum with the reference spectrum of calcein. As revealed by Figure 5.2C, both
their maximum emission and peak shape showed good agreement with each other. The detailed
TDI SFC data showed a maximum emission of 519.6 nm which was very close to the expected
maximum emission of calcein, 516 nm. These preliminary data demonstrated the reliability of
our TDI SFC system.
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After successfully detecting the bright calcein-stained cells, to further validate the
application of the TDI SFC, the same cell lines with weaker stains were tested. SUP-B15 B-
ALL cells were stained with 7-AAD and anti-TdT FITC and tested by the TDI SFC using the
same instrument parameters as calcein population. 7-AAD as a nuclear stain was used to make
sure that the event detected was truly from a cell but not from any interferent. TdT is a nucleus
enzyme that is positively expressed most ALL patients. 12 Thus, it was used as another detection
marker.
5.3.2 Multiplexed detection of B-ALL CLCs
We are currently participating in a pilot clinical study to detect relapse from MRD in B-
ALL patients by monitoring the number of CLCs in peripheral blood using microfluidic
enrichment of CD19(+) B-cells. The enriched B-cells are immunostained to specifically identify
CLCs. For this clinical application, we must differentiate CD19(+) normal cells from CD19(+)
CLCs. To accomplish this, immunophenotyping is employed and those that stain positive for
TdT are classified as CLCs. We chose 7-AAD as the nuclear stain for the TDI SFC system
because of its large Stokes shift (λmax = 647 nm), which enables multiplexing with dyes such as
FITC, PE, or tandem dyes. We evaluated the multiplexing capabilities of the TDI SFC by
analyzing mixtures of FITC and streptavidin conjugated with PE, PE-Cy5, PE-Cy7, or PerCP-
Cy5.5 using the TDI SFC. Least squares unmixing10 was used to deconvolute the resultant
spectra into the individual components and we found that we could correctly identify 11 different
dye mixtures (SI Figure 5.1 ).
As surrogates for CLCs, we stained a model B-ALL cell line (SUP-B15) that expressed
TdT. For the cell enumeration we used 7-AAD as the nuclear stain, and/ FITC-conjugated anti-
TdT Abs to check for TdT expression. In this cell line, we have consistently observed strong
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autofluorescence in ~6% of the SUP-B15 cells throughout normal culture conditions (Figure
5.3), which were likely a subpopulation of apoptotic cells.13 We differentiated these cells from
positive FITC-immunostaining of a membrane protein by morphological examination, where
immunostaining was exclusive to the membrane whereas autofluorescence was observed
throughout the cell.3 Rather than morphological examination by microscopy or imaging flow
cytometry,14 TDI SFC uses high spectral resolution to differentiate FITC’s or 7-AAD’s emission
from autofluorescence.
To evaluate the spectral properties of the fluorescent components, we processed SUP-
B15 cells that were fixed and permeabilized and either unstained (autofluorescence spectrum) or
stained with 7-AAD and/or anti-TdT-FITC Abs. The experimental TDI SFC emission spectra
matched well with reference spectra for the singly-stained controls (Figure 5.2) and served as a
training set for multiplexed spectral deconvolution.
Figure 5.2 Sample TDI SFC spectra (black lines) for FITC and 7-AAD compared to reference
spectra (colored lines)
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5.3.3 Autofluorescence in SUP-B15 B-ALL cell line
We observed autofluorescence in a subpopulation of SUP-B15 B-ALL cells that persisted
throughout normal culture conditions. In Figure 5.3, we show signal in the FITC channel by
fluorescence microscopy for a fraction of the SUP-B15 cells that we attributed to
autofluorescence with similar autofluorescence appearing in the Cy3 and Cy5 channels (data not
shown). To accurately quantitate how many SUP-B15 cells were autofluorescent, we
interrogated unstained cells by traditional flow cytometry (Figure 5.3B). We observed two
subpopulations of cells based on the forward scattering (FSC) signal. Approximately half of the
cells generated twice as much FSC signal as the other half, concordant with microscopic
examinations (Figure 5.3A). We suspect these cells were actively mitotic and therefore larger.
By examining signal in the FITC channel (Figure 5.3C), we observed that only a
subpopulation of the smaller cells (lower FSC) exhibited increased autofluorescence (~6.4% of
all cells in the FSC/SSC gate in Figure 5.3B). Given the lack of increased autofluorescence in
larger cells suspected to be mitotic, we hypothesize that roughly 6% of SUP-B15 cells are
apoptotic. We did not test this hypothesis due to interference of autofluorescence with standard
annexin V fluorescence staining. However, there is substantial literature precedence for
increased autofluorescence at 488 nm during apoptosis, particularly due to oxidation of
mitochondrial flavins, such as flavin adenine dinucleotide (FAD).13
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Figure 5.3 (A) Brightfield (grey) and fluorescence (FITC channel, green) microscopy images of
unstained SUP-B15 cells. Yellow arrows mark the presence of cells with increased
autofluorescence. All scale bars equal 100 µm. (B) Flow cytometry of unstained cells showed
two subpopulations (outlined by red) of cells with the same side scattering (SSC) signal but
differing forward scattering (FSC) signal. (C) Only the smaller cells (~6.4% of total cells) with
lower FSC signal exhibited increased autofluorescence on the FITC channel, whereas we found
no correlation between increased FITC signal and SSC. We also note that we observed similar
trends on all fluorescence channels (PE, PerCP, APC; data not shown)
5.3.4 Deconvolution of Multiplexed Fluorescence Spectra from B-ALL Cells
Classic least squares unmixing10 was unable to compensate for slight shifting of the
emission spectra with variation in the cells’ x-axis lateral position (Chapter 4 SI Figure 4.4C).
Thus, we fit each emission spectrum with multiple Gaussian functions and used a nonlinear least
squares solver with strict constraints (Figure 5.4A, Table 5.1) of the Gaussians’ relative
wavelength positions, standard deviations, and intensities. We note that singly-stained controls
need not be repeated as the fluorescent dye’s spectral properties remain constant.
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After processing the cells with the TDI SFC system, we background subtracted each
event and summed signals in all frames throughout a single event duration. These integrated
spectra were deconvoluted by curve fitting to determine the contribution of each fluorophore
component. Each curve, F(λ), was represented via sums of Gaussian functions:












In Eq. (5.1), If is the intensity of fluorophore f; Nf is the number of Gaussian functions for
fluorophore f; and Aif is the relative intensity of fluorophore f’s ith Gaussian function, which is
defined by the standard deviation in wavelength, σif, and the Gaussian’s peak position, Δλif, that
is set relative to the first Gaussian function, λ1f.
We used the unstained or singly-stained SUP-B15 cells to determine the curve fitting
parameters for autofluorescence and the 7-AAD and FITC fluorophores. We hand selected the 7-
AAD and FITC training sets to be reasonably devoid of autofluorescence components. These
spectra agreed well with reference spectra (Thermo Fisher Fluorescence SpectraViewer, Figure
5.2).
We note that slight variation in the cells’ lateral positions translated to shifting of the
fluorescence spectra along the CCD’s wavelength axis, generally by 1-5 nm. Thus, each
fluorophore’s components were not hard set but allowed to slightly shift in position and
magnitude according to constraints within a nonlinear, least squares solver. We outline the curve
fitting constraints as well as the median values observed in the training sets in Table 5.1 and
show the residuals, which were normalized to the maximum signal and averaged over every
event in the training set (Figure 5.4B). Lastly, we note that nonlinear least squares solvers are
highly susceptible to poor initial conditions for sums of exponentials. For multiplexed
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deconvolution, we first used the median values of fitting constraints in Table 5.1 to generate an
initial condition for a solution using variable fitting constraints.
Table 5.1 Curve fitting constraints for FITC, 7-AAD, and autofluorescence spectra that were










λ1 522-526 nm 523.7 nm
σ1 8-11 nm 9.6 nm
A2 1.00-1.00 1.00
Δλ2 11-14 nm 12.2 nm
σ2 11-17 nm 14 nm
A3 0.57-0.64 0.62
Δλ3 28-35 nm 31.4 nm
σ3 21-27 nm 22.9 nm
A4 0.18-0.23 0.21
Δλ4 60-66 nm 64 nm
σ4 32-38 nm 38 nm
A5 0.40-0.48 0.44
Δλ5 -10,-8 nm -8.9 nm




λ1 637-650 nm 638.8 nm
σ1 24-34 nm 28.5 nm
A2 1.00-1.00 1.00
λ2 25-35 nm 28.6 nm
σ2 33-43 nm 32.4 nm
A3 0.34-0.40 0.18
λ3 65-71 nm 94 nm
σ3 30-36 nm 63 nm
A4 0.15-0.21 0.37
λ4 88-94 nm 66.9 nm




λ1 518-521 nm 518.9 nm
σ1 6-8 nm 6.2 nm
A2 0.54-0.58 0.57
Δλ2 12-15 nm 13.4 nm
σ2 12-15 nm 13.5 nm
A3 0.78-0.82 0.64
Δλ3 31-34 nm 97.9 nm
σ3 19-23 nm 50.2 nm
A4 0.85-0.90 0.27
Δλ4 61-63 nm 146 nm
σ4 33-36 nm 77.3 nm
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Figure 5.4 (A) Sample spectra and fitting for FITC, 7-AAD, and autofluorescence, where the
raw data is shown in black beneath the fit curve. (B) After fitting all curves in the training set
using the constraints in Table 5.1, the average residual for the curve fitting was computed and
normalized to the maximum signal in the raw data.
We excluded highly autofluorescent SUB-15 cells (SI Figure 4.2) and differentiated
normal B-cells (cells stained positive for 7-AAD only) from CLCs (cells stained positive for both
7-AAD and anti-TdT-FITC Abs). By multiplexed deconvolution, TDI SFC identified 100% of
cells as singly-stained and correctly identified 99.1% of the CLCs as positive for both markers
using the TDI SFC system (Figure 5.5 A). We observed slightly higher median Sint signals for 7-
AAD (1.7×105 counts) compared to anti-TdT-FITC Abs (1.1×105 counts), but equivalent SNR
(175) for the stains (Figure 5.5 B).
A5 0.62-0.66 0.81
Δλ5 96-99 nm 33.7 nm
σ5 48-51 nm 22.4 nm
A6 0.27-0.31 0.90
Δλ6 142-146 nm 62.4 nm
σ6 74-79 nm 34.6 nm
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Figure 5.5 (A) Multiplexed deconvolution correctly classified 100% of singly-stained cells and
99.1% of dual-stained model CLCs. (B) Box plots of Sint and SNR for 7-AAD or anti-TdT-FITC
staining.
TDI SFC classification was based on each cell’s unique fluorescence emission spectrum.
This is in contrast to conventional flow cytometry, where emission is spectrally binned and cells
with similar emission intensities are clustered for identification. This unique aspect of TDI SFC
spectral deconvolution enabled us to achieve high accuracy in classifying cells even at low cell
numbers (46-111 cells per group) that would normally be difficult for traditional flow cytometry.
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5.4 Conclusions
As a demonstration of the utility of the TDI SFC, we processed B-ALL cells stained with
a nuclear dye (7-AAD) and a leukemic marker (anti-TdT-FITC). A ~100% classification
accuracy was secured for the CLCs by deconvoluting TDI SFC spectra for each cell, which were
readout with high signal (106 integrated counts) and SNR (175), at cell numbers (46-111 cells)
that would be prohibitive for traditional MFC. We provided further evidence for the spectral
deconvolution of 5 multiplexed dyes and compared TDI SFC performance to a commercial MFC
instrument (97% concordance for cell detection efficiency).
Limitations of the current TDI SFC instrument was the relatively modest throughput; 90
events/min. This was a result of the limited readout rate of the CCD used herein; lower serial
register readout times can improve this. Also, in the current format of the TDI SFC, the CV was
27.8% compared to 5% for the commercial MFC. This was due to the 1D microfluidic focusing
employed herein. Future renditions of this TDI SFC instrument will seek to use 2-D microfluidic
focusing to ensure that all cells are focused to the focal plane of the epi-illumination objective






1 Classic least square unmixing of dye mixtures
2 Autofluorescence in SUP-B15 B-ALL cell line
1. Classic least squares unmixing of dye mixtures
We infused mixtures of FITC (1 nM), streptavidin-PE (5 nM), streptavidin-PE-Cy5 (5
nM), and/or streptavidin-PE-Cy7 (50 nM) through a glass capillary. For every possible
combination of dyes, results from classic least squares unmixing10 correctly identified each
mixture’s composition (SI Figure 5.1) without false positives or negatives.
SI Figure 5.1 Mixtures of FITC (F), PE (P), PE-Cy5 (5), and PE-Cy7 (7) were imaged using the
TDI-SFC system. Along the columns, mixtures are designated by their components, where FP
includes FITC and PE but not PE-Cy5 or PE-Cy7 and FP57 includes all components. Resultant
spectra were deconvoluted by classic least squares unmixing, and the dyes detected for each
mixture are shown along the rows. If a dye was detected in the mixture, the cell is colored and
labeled, whereas if the dye was not detected by deconvolution, the cell is grey and marked with a
dash. For every mixture tested, the system correctly identified the dye components without any
false positives.
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2. Autofluorescence in SUP-B15 B-ALL cell line
SUP-B15 cells were autofluorescent. Autofluorescence spectra overlapped significantly
with both FITC and 7-AAD spectra (Figure 5.4A), so we sought to eliminate interfering
autofluorescence by deconvolution. We examined the percentage of autofluorescence signal in
each event (SI Figure 5.2). All unstained cells had little signal attributed to either FITC or 7-
AAD by deconvolution, whereas most stained cells had <25% autofluorescence. Thus, in
subsequent analysis we excluded cells with ≥25% autofluorescence signal.
SI Figure 5.2 Percentage of signal originating from autofluorescence by multiplexed spectral
deconvolution. In all subsequent analyses, cells with ≥25% autofluorescence were excluded.
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Conclusions and Future Directions
6.1 Summary and Conclusion
Leukemia is a serious health concern that necessitates more sensitive methods for
monitoring rare MRD in PB instead of invasive BM biopsies. Our group previously developed a
microfluidic assay for CLC monitoring in AML patients’ PB samples with a sensitivity of 10-5-
10-6 compared with a sensitivity of 1-5%1 with morphology and 10-3-10-4 with traditional flow
cytometry.2 The chip-isolated cells in this microfluidic assay were enumerated and
immunophenotyped by semi-automated fluorescence microscopy. But we would like to increase
the automation of the immunophenotyping process. Flow cytometry is a commonly used method
for cell immunophenotyping with higher throughput than fluorescence microscopy. However,
because the number of cells isolated in our microfluidic assay is normally in the range of 100-
10,000, these cells are not adequate for immunophenotyping in traditional flow cytometry due to
the requirement of extra sample for setting up proper gattings and performing spectra
compensation. Therefore, we developed a TDI SFC for chip-isolated cell enumeration and
immunophenotyping with the ultimate goal of closely monitoring CLCs in acute leukemia
patients, especially in B-ALL adolescent leukemia patients.
The TDI SFC has the following unique features. 1) It operates in a TDI mode. With TDI,
when the cell’s linear velocity is synchronized with the TDI CCD’s readout rate the
photoelectrical signal will be integrated in only a few pixel rows at readout, increasing SNR than
the normal full frame readout.3 2) There is no shutter needed during TDI data acquisition because
the exposure and readout occur simultaneously. This resulted in nearly 100% duty cycle, greatly
reduced the possibility of missing cells.
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We carefully characterized the TDI SFC with stable, uniform and bright fluorescent latex
beads in several aspects. 1) We fabricated a microfluidic flow cell to hydrodynamically focus the
cell sample to increase the uniformity of the cells’ linear velocities. A square capillary was also
used as a flow device to confirm the benefit of hydrodynamic focusing the in microfluidic flow
cell. 2) We found out the optimal sample and sheath flow rates in the microfluidic flow cell to
synchronize the analytes with the TDI CCD’s readout. 3) Various optimizations were performed
to further increase the fluorescent signal and SNR. 4) Detection efficiency and throughput were
investigated to find out the upper limit of throughput of our system
After the characterizations and optimizations, we applied the TDI SFC to a proof-of-
concept application to validate its potential in leukemic MRD monitoring. SUP-B15 B-ALL
leukemic cells were stained with against markers and tested in the system. The TDI SFC
successfully detected the cell events from each population stained with different markers. It also
successfully detected some unexpected events in the unstained negative control. We suspect
these events were mainly from autofluorescent cells. We also developed and optimized custom-
developed spectra unmixing algorithms to perform spectra deconvolution on the TDI SFC data.
By using the spectra of singly stained and unstained cell populations as training set, the
algorithms successfully resolved each component spectrum in the dually stained cell population
and identified 99.1% of the cells as positive for both markers. All these data demonstrated the
great potential of our TDI SFC in enumerating and immunophenotyping chip-isolated CLCs
from leukemia patients’ peripheral blood.
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6.2 Future Direction
6.2.1 2D Focusing Microfluidic chip
There are several aspects where improvement can be made to make the TDI SFC’s
performance better and facilitate its great potential in monitoring MRD in leukemia patients. One
will be using a 2D focusing chip instead of 1D focusing chip. The current microfluidic flow cell
provides 1D focusing only on the lateral axis (x axis in the schematic in Figure 4.1). There is no
flow focusing on the z axis where the channel depth is 93 µm. As a result, the cells can be spread
out at the channel depth of 93 µm, which is much more than the depth of field of the optical
system.
On the object plane, depth of field Z defines the depth along the z axis where the objects
of the specimen is in focus.4 For diffraction-limited optical systems, Z can be expressed as
Z = n  NA2 (Eq. 6.1)
where n is the refractive index of the medium between the lens and the object, which is 1.0003
here; λ is the wavelength of light in air, which is 515 nm for FITC here; and NA is the numerical
aperture of the objective lens. Thus, Z (10x) is 2.08 µm and Z (20x) is 0.9 µm in our TDI SFC
system.
When the specimen is out of the depth of field, it is not well-focused by the optical
system any more, leading to low quality image or no signal at all. Specifically in our system, if
the cell is at the top or bottom of the microfluidic channel, it will be possible that only weak
signal is obtained or the cell is not detected at all (Figure 6.1A). This is especially true for dimly
expressed markers on cells. For brightly expressed markers on cells, this imperfection results in
position-dependent fluorescence signal within cells that expressed exactly the same level of
target markers. For two cells that express exactly the same amount of markers, the cell perfectly
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within the depth of field would have more photons detected than the cell out of the depth of field,
causing different signals detected by the TDI SFC system. Since this signal difference is due to
the different positions of the cells but not the marker expression level difference in the cells, it
should be substantially minimized. An alternative to solve this problem is to develop
microfluidic flow cells capable of 2D focusing5 (Figure 6.1B).
Figure 6.1 (A) 1D hydrodynamic focusing in our current microfluidic flow cell. Due to the fact
that the channel depth is much more than the depth of field of the optical system, when the cells
are out of the depth of field, for example, they are at the top or bottom of the microfluidic
channel, it is possible that these cells are not detected by the TDI SFC. (B) An alternative to
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To make our TDI SFC capable of better performance, we fabricated a mold for
fabricating microfluidic flow cells that could provide 2D hydrodynamic focusing. Figure 6.2
shows the mold, a successfully bonded chip, and the schematic of 2D focusing in this chip
Figure 6.2 2D focusing microfluidic flow cell. (A) The brass mold for fabricating the
microfluidic flow cell capable of 2D focusing. (B) A successfully bonded 2D focusing microchip.
(C) The schematic of the 2D focusing in the microchip. The mold structure was transferred to
both the coverslip and the substrate before chip bonding. The sheath fluid can not only focus the
sample flow on the horizontal direction but also on the vertical direction, allowing for 2D
focusing.
Whether this 2D focusing chip is applicable in our TDI SFC system is unknown. Tests
with fluorescent calibration beads in this chip are needed to reveal whether such low flow rate
necessary for the TDI CCD synchronization is applicable in this microfluidic chip. This is
because when using a syringe pump to introduce sample fluid to the microfluidic chip, there is a
lower limit of flow rate that can be realized due to mechanical reasons in the pump. Specifically,
there is a lower limit of frequency on the pump motor to push the syringe plunger when
introducing samples into the microfluidic chip. If such low flow rate necessary for current TDI
synchronization is not applicable in the 2D focusing chip, one solution will be increasing the
frame rate of the TDI CCD to facilitate faster flow rate of the samples.
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6.2.2 Faster Frame Rate
Another modification that can improve the performance of the system is to improve the
CCD camera’s frame rate. If the frame rate is faster, the cell samples can move faster in the
microfluidic channel. This can not only improve the throughput and make data collection more
time-efficient, but also can reduce the probability of the cells’ sedimentation in the fluidic system
and obtain higher detection efficiency. One way to achieve this is to use binning on the pixels.
For instance, if x=2, y=1 binning is used, for each pixel row there will be 670 pixels to be read
out instead 1340 pixels, allowing for faster frame rate. One drawback it brings is the decreased
spectral resolution. With x=2 binning, the spectral resolution is decreased from 0.7 nm/pixel to
1.4 nm/pixel. However, this decrease is not detrimental since a spectral resolution of 1.4
nm/pixel is still relatively high. We already carried out experiments on this idea. However, the
readout time per pixel row decreased from about 2 ms to 1.7 ms (data not shown here). This
minor decrease is not able to provide tremendous improve on frame rate. Another way to
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